# 2025年10月26日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 不同年龄组胶质母细胞瘤患者超最大范围切除与预后的关联：RANO切除组报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137668](https://pubmed.ncbi.nlm.nih.gov/41137668)
**期刊：** Neuro-oncology
**PMID：** 41137668
**DOI：** 10.1093/neuonc/noaf239

### 第一部分 原文与翻译

**英文原标题：** Associations of supramaximal resection with outcome in glioblastoma across age groups: a report of the RANO resect group.

**英文摘要原文：**
BACKGROUND: The oncological role of resection in elderly patients with glioblastoma remains controversial. We evaluated the value of resection in patients ≥65 years with (I) newly diagnosed and (II) recurrent glioblastoma by comparing the prognostic relevance of extent of resection to patients <65 years.

METHODS: The international RANO resect group retrospectively collected patients with newly diagnosed and recurrent IDH-wildtype glioblastoma from ten neuro-oncological centers. Associations of residual tumor with molecular and clinical markers and survival were analyzed.

RESULTS: 1260 patients with newly diagnosed glioblastoma were identified, including 512 patients ≥65 years. Lower postoperative contrast-enhancing tumor volumes were favorably associated with survival on uni- and multivariate analyses; however, the associations with outcome were more pronounced in younger patients. Only in patients <65 years, supramaximal resection was associated with more favorable survival (40 vs. 20 months, p=0.001). In 310 patients with first recurrence (≥65 years: 92), maximal resection of contrast-enhancing tumor was associated with favorable outcomes, particularly in younger patients. Neither older nor younger patients had favorable outcome associations of supramaximal resection in the recurrent setting. All findings were confirmed in propensity-score-matched analyses to minimize confounding effects of inherent differences in demographic and clinical markers (including second-line treatments) between older and younger patients.

CONCLUSIONS: While complete contrast-enhancing tumor resection is prognostic for favorable outcomes in older patients, associations of supramaximal resection with improved outcomes were only retained in younger patients with newly diagnosed disease. Those findings support stratified surgical approaches.

**中文摘要译文：**
背景：胶质母细胞瘤老年患者中切除术的肿瘤学作用仍存在争议。我们通过比较切除范围对≥65岁和<65岁患者的预后相关性，评估了切除术在（I）新诊断和（II）复发性胶质母细胞瘤≥65岁患者中的价值。

方法：国际RANO切除组回顾性收集了来自十个神经肿瘤中心的新诊断和复发性IDH野生型胶质母细胞瘤患者。分析了残留肿瘤与分子和临床标志物以及生存期的关联。

结果：共确定了1260例新诊断胶质母细胞瘤患者，其中包括512例≥65岁患者。在单变量和多变量分析中，较低的术后对比增强肿瘤体积与较好的生存期相关；然而，这种与预后的关联在年轻患者中更为明显。仅在<65岁患者中，超最大范围切除与更有利的生存期相关（40个月 vs. 20个月，p=0.001）。在310例首次复发患者中（≥65岁：92例），对比增强肿瘤的最大范围切除与良好预后相关，特别是在年轻患者中。在复发情况下，无论是老年还是年轻患者，超最大范围切除均未显示出与良好预后的关联。所有发现在倾向评分匹配分析中得到确认，以最小化老年和年轻患者之间人口统计学和临床标志物（包括二线治疗）固有差异的混杂效应。

结论：虽然完全对比增强肿瘤切除可预测老年患者的良好预后，但超最大范围切除与改善预后的关联仅在新诊断疾病的年轻患者中保留。这些发现支持分层手术方法。

### 第二部分 AI 大师评价

本研究通过国际多中心回顾性分析，系统评估了不同年龄组胶质母细胞瘤患者手术切除范围与预后的关系。研究创新性地揭示了年龄分层在胶质母细胞瘤手术策略中的重要性：虽然完全切除对比增强肿瘤对老年患者有益，但超最大范围切除的生存获益仅见于新诊断的年轻患者。该研究采用倾向评分匹配分析有效控制了混杂因素，为个体化手术决策提供了高质量循证依据。然而，作为回顾性研究，仍需前瞻性验证来确认这些发现，但其结果已为胶质母细胞瘤的年龄分层治疗策略奠定了重要基础。

---

## 2. 人血浆样培养基中的稳定同位素示踪揭示胶质母细胞瘤微环境的代谢与免疫调控

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137658](https://pubmed.ncbi.nlm.nih.gov/41137658)
**期刊：** Neuro-oncology
**PMID：** 41137658
**DOI：** 10.1093/neuonc/noaf248

### 第一部分 原文与翻译

**英文原标题：** Stable isotope tracing in human plasma-like medium reveals metabolic and immune modulation of the glioblastoma microenvironment.

**英文摘要原文：**
BACKGROUND: In vivo stable isotope tracing is useful for natively surveying glioma metabolism but can be difficult to implement. Stable isotope tracing is tractable using in vitro glioma models, but most models lack nutrient conditions and cell populations relevant to human gliomas. This limits our ability to study glioma metabolism in the presence of an intact tumor microenvironment (TME) and immune-metabolic crosstalk.

METHODS: We optimized an in vitro stable isotope tracing approach for human glioma explants and glioma stem-like cell (GSC) lines that integrates human plasma-like medium (HPLM). We performed 15N2-glutamine tracing in GSC monocultures and human IDH-wildtype glioblastoma explants and developed an analytical framework to evaluate microenvironment-dependent metabolic features that distinguish them. We also conducted spatial transcriptomics to assess transcriptional correlates to metabolic activities.

RESULTS: HPLM culture preserved glioma explant viability and stemness while unmasking metabolic and immune programs suppressed by conventional culture conditions. Stable isotope tracing in HPLM revealed TME-dependent and TME-independent features of tumor metabolism. Tissue explants recapitulated tumor cell-intrinsic metabolic activities, such as synthesis of immunomodulatory purines. Unlike GSC monocultures, tissue explants captured tumor cell-extrinsic activities associated with stromal cell metabolism, as exemplified by astrocytic GDP-mannose production in heterocellular explants. Finally, glioma explants displayed tumor subtype-specific metabolic reprogramming, including robust pyrimidine degradation in mesenchymal cells.

CONCLUSIONS: We present a tractable approach to assess glioma metabolism in vitro under physiologic nutrient levels and in the presence of an intact TME. This平台 opens new avenues to interrogate glioma metabolism and its interplay with the immune microenvironment.

**中文摘要译文：**
背景：体内稳定同位素示踪有助于原生状态下研究胶质瘤代谢，但实施难度较大。使用体外胶质瘤模型进行稳定同位素示踪较为可行，但大多数模型缺乏与人类胶质瘤相关的营养条件和细胞群体。这限制了我们在完整肿瘤微环境（TME）和免疫代谢相互作用存在的情况下研究胶质瘤代谢的能力。

方法：我们优化了一种用于人胶质瘤外植体和胶质瘤干细胞（GSC）系的体外稳定同位素示踪方法，该方法整合了人血浆样培养基（HPLM）。我们在GSC单培养和人IDH野生型胶质母细胞瘤外植体中进行了15N2-谷氨酰胺示踪，并开发了一个分析框架来评估区分它们的微环境依赖性代谢特征。我们还进行了空间转录组学分析，以评估与代谢活动相关的转录相关性。

结果：HPLM培养在保持胶质瘤外植体活性和干细胞特性的同时，揭示了传统培养条件所抑制的代谢和免疫程序。HPLM中的稳定同位素示踪揭示了肿瘤代谢的TME依赖性和TME非依赖性特征。组织外植体重现了肿瘤细胞固有的代谢活动，如免疫调节性嘌呤的合成。与GSC单培养不同，组织外植体捕获了与基质细胞代谢相关的肿瘤细胞外在活动，例如异细胞外植体中星形胶质细胞的GDP-甘露糖产生。最后，胶质瘤外植体显示出肿瘤亚型特异性的代谢重编程，包括间充质细胞中强烈的嘧啶降解。

结论：我们提出了一种可行的方法，在生理营养水平和完整TME存在的情况下体外评估胶质瘤代谢。该平台为探索胶质瘤代谢及其与免疫微环境的相互作用开辟了新途径。

### 第二部分 AI 大师评价

本研究开发了一种创新的体外胶质瘤代谢研究平台，通过整合人血浆样培养基（HPLM）和稳定同位素示踪技术，成功克服了传统体外模型的局限性。该方法的创新性在于能够在生理营养条件下维持完整肿瘤微环境，同时揭示胶质瘤细胞与基质细胞间的代谢相互作用。研究发现不仅识别了肿瘤细胞固有的免疫调节代谢特征，还发现了亚型特异性的代谢重编程模式，特别是间充质亚型中显著的嘧啶降解。这一平台为深入理解胶质瘤代谢异质性及其与免疫微环境的复杂互作提供了重要工具，具有推动胶质瘤精准治疗发展的潜在临床价值。虽然该研究主要聚焦于方法学开发，但其建立的标准化分析框架有望成为未来胶质瘤代谢研究的重要基准。

---

## 3. 子宫内膜息肉的基因组图谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137179](https://pubmed.ncbi.nlm.nih.gov/41137179)
**期刊：** Genome medicine
**PMID：** 41137179
**DOI：** 10.1186/s13073-025-01556-z

### 第一部分 原文与翻译

**英文原标题：** Genomic landscape of endometrial polyps.

**英文摘要原文：**
BACKGROUND: Endometrial polyps are common, localized overgrowths of endometrial glands and stroma that protrude into the uterine cavity. These tumor-like lesions can cause symptoms like abnormal uterine bleeding and infertility, and they may undergo malignant transformation. The etiology of endometrial polyps remains largely unknown.

METHODS: Here, we conducted whole-genome sequencing and global gene expression profiling on 23 polyps. Major findings were validated with targeted DNA (Sanger sequencing) and protein (immunohistochemistry) level analyses. Sanger sequencing was also utilized to validate the observed novel alterations in an additional set of 54 polyp samples.

RESULTS: The most common alterations were chromosomal rearrangements affecting HMGA1 and HMGA2, identified in 74% (17/23) of the polyps. These rearrangements involved LRMDA, RAD51B, TRAF3IP2, and 7p15.2 as recurrent rearrangement partners. 3'RNA sequencing indicated corresponding overexpression of HMGA1 and HMGA2 as well as a downstream target PLAG1. Elevated protein level expression of HMGA1 and HMGA2 was further shown using immunohistochemistry. In addition to frequent HMGA1 and HMGA2 alterations, we found UBE2A as a novel candidate driver gene with highly specific recurrent mutations. We also identified recurrent low-allelic fraction mutations in well-established cancer genes KRAS, PIK3CA, PIK3R1, and PTEN.

CONCLUSIONS: Here, we have characterized the genomic landscape of endometrial polyps. We show that chromosomal alterations affecting HMGA1 and HMGA2 are a major underlying cause for polyp development. In addition, we present UBE2A as a novel candidate gene for human tumorigenesis. Our results contribute to a better understanding of endometrial polyp development and pave the way towards the development of targeted, non-invasive treatment options.

**中文摘要译文：**
背景：子宫内膜息肉是常见的局部过度生长，由子宫内膜腺体和间质组成，突出于子宫腔内。这些肿瘤样病变可引起异常子宫出血和不孕等症状，并可能发生恶性转化。子宫内膜息肉的病因在很大程度上仍然未知。

方法：在此，我们对23例息肉进行了全基因组测序和全局基因表达谱分析。主要发现通过靶向DNA（Sanger测序）和蛋白质（免疫组织化学）水平分析进行了验证。Sanger测序还被用于在另外一组54个息肉样本中验证观察到的新改变。

结果：最常见的改变是影响HMGA1和HMGA2的染色体重排，在74%（17/23）的息肉中被鉴定出来。这些重排涉及LRMDA、RAD51B、TRAF3IP2和7p15.2作为复发性重排伙伴。3'RNA测序表明HMGA1和HMGA2以及下游靶点PLAG1的相应过表达。使用免疫组织化学进一步显示了HMGA1和HMGA2蛋白水平表达的升高。除了频繁的HMGA1和HMGA2改变外，我们发现UBE2A作为一个新的候选驱动基因，具有高度特异性的复发性突变。我们还确定了在已确立的癌症基因KRAS、PIK3CA、PIK3R1和PTEN中复发性低等位基因分数突变。

结论：在此，我们描述了子宫内膜息肉的基因组图谱。我们表明影响HMGA1和HMGA2的染色体改变是息肉发展的主要潜在原因。此外，我们提出UBE2A作为人类肿瘤发生的一个新候选基因。我们的结果有助于更好地理解子宫内膜息肉的发展，并为开发靶向、非侵入性治疗方案铺平道路。

### 第二部分 AI 大师评价

本研究通过全基因组测序和基因表达分析系统揭示了子宫内膜息肉的基因组特征，具有重要的创新价值。研究团队采用多组学方法，在23例息肉样本中发现了HMGA1/HMGA2染色体重排是息肉形成的主要机制（占74%），并首次提出UBE2A作为新的候选驱动基因。该研究不仅阐明了子宫内膜息肉的分子发病机制，还发现了与已知癌症基因相关的低频突变，为理解息肉向恶性肿瘤转化的潜在风险提供了分子基础。研究成果为开发靶向治疗策略奠定了理论基础，但样本量相对有限，未来需要在更大队列中验证这些发现。

---

## 4. 克隆性造血中的种族差异及其对血液系统恶性肿瘤的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137150](https://pubmed.ncbi.nlm.nih.gov/41137150)
**期刊：** Journal of hematology & oncology
**PMID：** 41137150
**DOI：** 10.1186/s13045-025-01740-z

### 第一部分 原文与翻译

**英文原标题：** Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies.

**英文摘要原文：**
Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for hematologic malignancies (HM), but its distribution and clinical implications across diverse ancestries remain poorly characterized. In this study, we investigated CHIP and its progression to HM in a large, racially diverse cohort from the All of Us Research Program, comprising 245,388 participants. We identified 10,446 CHIP driver mutations in 9,476 individuals. Our analysis revealed clear racial disparities in CHIP prevalence and mutational profiles: African American (AA) individuals had higher odds of CHIP and exhibited distinct mutation patterns compared to White American (WA) individuals. Consistent with prior studies, CHIP was associated with an increased risk of HM, particularly myeloid malignancies. Notably, ancestry influenced the subtype of myeloid malignancy observed; CHIP was more strongly linked to myeloproliferative neoplasms in AA individuals compared with WA individuals. These findings demonstrated significant racial differences in CHIP biology and HM progression, highlighting the need for ancestry-informed approaches to CHIP risk assessment and HM prevention.

**中文摘要译文：**
意义未明的克隆性造血（CHIP）是血液系统恶性肿瘤（HM）的已知危险因素，但其在不同种族群体中的分布和临床意义仍不清楚。在本研究中，我们调查了来自"我们所有人"研究计划的245,388名参与者组成的大型多种族队列中的CHIP及其向HM的进展。我们在9,476名个体中识别出10,446个CHIP驱动突变。我们的分析揭示了CHIP患病率和突变谱的明显种族差异：与非裔美国人相比，非裔美国人（AA）个体患CHIP的几率更高，并表现出不同的突变模式。与先前研究一致，CHIP与HM风险增加相关，特别是髓系恶性肿瘤。值得注意的是，种族背景影响了观察到的髓系恶性肿瘤亚型；与非裔美国人相比，CHIP在非裔美国人个体中与骨髓增殖性肿瘤的相关性更强。这些发现证明了CHIP生物学和HM进展中存在显著的种族差异，突显了需要基于种族背景的方法来进行CHIP风险评估和HM预防。

### 第二部分 AI 大师评价

本研究通过分析"我们所有人"研究计划中245,388名多种族参与者，系统揭示了克隆性造血（CHIP）在不同种族群体中的分布差异及其对血液系统恶性肿瘤的影响。研究创新性地发现非裔美国人不仅CHIP患病率更高，而且表现出独特的突变谱，且CHIP与非裔美国人骨髓增殖性肿瘤的相关性更强。这一发现具有重要的临床价值，强调了在血液系统恶性肿瘤风险评估和预防中考虑种族背景的必要性。研究的局限性在于主要基于观察性数据，需要进一步机制研究来阐明种族差异的生物学基础。

---

## 5. B细胞成熟抗原是急性髓系白血病免疫治疗的新靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137079](https://pubmed.ncbi.nlm.nih.gov/41137079)
**期刊：** Journal of hematology & oncology
**PMID：** 41137079
**DOI：** 10.1186/s13045-025-01741-y

### 第一部分 原文与翻译

**英文原标题：** B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.

**英文摘要原文：**
B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In this study, we demonstrate through RNA sequencing and flow cytometry analyses of acute myeloid leukemia (AML) cell lines and primary patient samples that BCMA is also a relevant AML-associated antigen. Its robust surface expression on AML cells positions it as a promising candidate for targeted immunotherapy. Functionally, our findings indicate that BCMA in AML operates similarly to its role in MM - engaging the NF-kB pathway upon ligand binding, thereby activating gene expression programs that support leukemia cell survival and proliferation. We assessed several BCMA-targeted immunotherapeutic strategies, including bispecific T-cell engagers (TCE) and chimeric antigen receptor (CAR) transduced T-cells, NK-cells, and macrophages. We found that TCE treatment and BCMA CAR engineering markedly improved effector cell mediated cytotoxicity against AML cells, underscoring BCMA's potential as a viable therapeutic target in AML. Furthermore, BCMA- directed TCE therapy significantly augmented the anti-leukemic activity of adoptively transferred CD8 T-cells in a human AML xenograft model. Taken together, these findings support BCMA as a novel immunotherapeutic target in AML. Leveraging existing BCMA-directed treatments developed for MM could enable rapid clinical translation and broaden immunotherapy options for patients with AML.

**中文摘要译文：**
B细胞成熟抗原（BCMA）因其在多发性骨髓瘤细胞、浆细胞和成熟B细胞上的限制性表达，而在其他正常组织中表达极少，已成为多发性骨髓瘤（MM）的重要免疫治疗靶点。在本研究中，我们通过对急性髓系白血病（AML）细胞系和原代患者样本进行RNA测序和流式细胞术分析，证明BCMA也是一个相关的AML相关抗原。其在AML细胞上的强表面表达使其成为靶向免疫治疗的有前景候选靶点。功能上，我们的发现表明AML中的BCMA与其在MM中的作用相似——在配体结合后激活NF-kB通路，从而激活支持白血病细胞存活和增殖的基因表达程序。我们评估了几种BCMA靶向免疫治疗策略，包括双特异性T细胞衔接器（TCE）和嵌合抗原受体（CAR）转导的T细胞、NK细胞和巨噬细胞。我们发现TCE治疗和BCMA CAR工程显著改善了效应细胞介导的对AML细胞的细胞毒性，强调了BCMA作为AML可行治疗靶点的潜力。此外，在人类AML异种移植模型中，BCMA导向的TCE治疗显著增强了过继转移CD8 T细胞的抗白血病活性。综上所述，这些发现支持BCMA作为AML中新的免疫治疗靶点。利用为MM开发的现有BCMA导向治疗方法可以实现快速的临床转化，并为AML患者拓宽免疫治疗选择。

### 第二部分 AI 大师评价

本研究核心目的是探索B细胞成熟抗原（BCMA）作为急性髓系白血病（AML）免疫治疗新靶点的可行性。研究团队通过RNA测序和流式细胞术分析，系统评估了BCMA在AML细胞中的表达和功能特性。关键发现证实BCMA在AML细胞表面高表达，且通过激活NF-kB通路促进白血病细胞存活增殖；更重要的是，BCMA靶向的T细胞衔接器和CAR-T治疗在体外和体内模型中均显示出显著的抗白血病活性。这项研究的创新性在于将已在多发性骨髓瘤中验证的BCMA靶向治疗策略成功拓展至AML领域，具有重要的临床转化价值，有望为AML患者提供新的治疗选择。然而，研究仍需进一步验证BCMA在AML不同亚型中的表达异质性以及长期治疗的安全性。

---

## 6. 基因组编辑的同种异体CAR-T细胞：下一代癌症免疫疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137066](https://pubmed.ncbi.nlm.nih.gov/41137066)
**期刊：** Journal of hematology & oncology
**PMID：** 41137066
**DOI：** 10.1186/s13045-025-01745-8

### 第一部分 原文与翻译

**英文原标题：** Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies.

**英文摘要原文：**
Chimeric Antigen Receptor T (CAR-T) cell therapy has revolutionized cancer immunotherapy, particularly in hematological malignancies. However, the clinical application of autologous CAR-T cells faces significant high cost and manufacturing challenges. Universal allogeneic CAR-T cells, derived from healthy donors, represent a promising solution to these obstacles. These "off-the-shelf" therapies aim to reduce the complexity and cost of CAR-T production. Despite exciting advancements in genome-editing technologies and promising clinical trial data, significant challenges remain, including graft-versus-host disease (GVHD), Host-versus-graft reaction (HVGR), off-target effects, genotoxicity, and manufacturing scalability. To address these concerns, genome-editing technologies such as ZFNs, TALENs, Meganucleases, CRISPR systems, base editing, and prime editing are being employed. This review summarizes the progress of universal allogeneic CAR-T cell therapies, addresses the critical challenges, and discusses the future directions for their临床实施.

**中文摘要译文：**
嵌合抗原受体T（CAR-T）细胞疗法已经彻底改变了癌症免疫治疗，特别是在血液系统恶性肿瘤中。然而，自体CAR-T细胞的临床应用面临着显著的高成本和制造挑战。来自健康供体的通用同种异体CAR-T细胞代表了解决这些障碍的有前景方案。这些"现货"疗法旨在降低CAR-T生产的复杂性和成本。尽管基因组编辑技术取得了令人兴奋的进展，临床试验数据也显示出希望，但仍存在重大挑战，包括移植物抗宿主病（GVHD）、宿主抗移植物反应（HVGR）、脱靶效应、遗传毒性和制造可扩展性。为了解决这些问题，正在采用ZFNs、TALENs、巨核酸酶、CRISPR系统、碱基编辑和先导编辑等基因组编辑技术。本综述总结了通用同种异体CAR-T细胞疗法的进展，解决了关键挑战，并讨论了其临床实施的未来方向。

### 第二部分 AI 大师评价

本研究系统综述了基因组编辑的同种异体CAR-T细胞作为下一代癌症免疫疗法的发展现状。该研究聚焦于解决自体CAR-T细胞疗法面临的高成本和制造挑战，通过采用ZFNs、TALENs、CRISPR等多种基因组编辑技术来开发"现货"通用型CAR-T产品。研究创新性地整合了多种前沿基因编辑工具，为解决GVHD、HVGR等关键临床障碍提供了技术路径。尽管该领域在技术层面取得了显著进展，但仍需克服脱靶效应、遗传毒性和规模化生产等挑战，其临床转化潜力值得期待，有望推动癌症免疫治疗进入新的发展阶段。

---

## 7. 滤泡性淋巴瘤结外受累的临床特征与分子异质性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137062](https://pubmed.ncbi.nlm.nih.gov/41137062)
**期刊：** Genome medicine
**PMID：** 41137062
**DOI：** 10.1186/s13073-025-01557-y

### 第一部分 原文与翻译

**英文原标题：** Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.

**英文摘要原文：**
BACKGROUND: Follicular lymphoma (FL) represents the most common subtype of indolent non-Hodgkin's lymphoma. Extranodal involvement (ENI) indicates a poor clinical outcome in patients who received rituximab-based immunochemotherapy. Recent studies indicate that genetic alterations and tumor microenvironment dysregulation drive extranodal dissemination and lymphoma progression. However, the molecular mechanisms underlying ENI in FL remain to be fully elucidated.

METHODS: Aiming to investigate the influence of oncogenic mutations and tumor microenvironment alterations on ENI in FL, the clinical features of 501 patients with newly diagnosed FL receiving rituximab-based therapy were analyzed, with DNA and RNA sequencing performed on 403 and 175 patients, respectively.

RESULTS: Multiple ENI was observed in 120 (24%) patients and was significantly related to advanced Ann Arbor stage, decreased hemoglobin, elevated lactate dehydrogenase, elevated beta-2 microglobulin, lymph nodes ≥ 5 sites, lymph nodes > 6 cm, and high risk of progression of disease within 2 years (POD24). Increased KMT2D, CREBBP, CARD11, and STAT6 mutations, as well as downregulation of immune-associated pathways and alterations in lipid metabolism, were associated with multiple ENI. In the rituximab plus chemotherapy (R-chemo) cohort (n = 344), involvement of bone marrow, lung, liver, bones, and kidney/adrenal glands were unfavorable predictors of progression-free survival (PFS), with involvement of liver and kidney/adrenal glands as unfavorable predictors of overall survival (OS). However, in the rituximab plus lenalidomide immunotherapy (R2) cohort (n = 157), no ENI site showed a significant difference in PFS and OS.

CONCLUSIONS: Negative prognostic impact of multiple ENI upon R-chemo therapy could be overcome by R2 therapy in FL. Better understanding of the biological behavior of multiple ENI could provide a potential clinical rationale for future mechanism-based therapy of FL.

**中文摘要译文：**
背景：滤泡性淋巴瘤（FL）是最常见的惰性非霍奇金淋巴瘤亚型。在接受利妥昔单抗为基础的免疫化疗的患者中，结外受累（ENI）预示着不良的临床结局。近期研究表明，基因改变和肿瘤微环境失调驱动了结外播散和淋巴瘤进展。然而，FL中ENI的分子机制仍有待完全阐明。

方法：为了研究致癌突变和肿瘤微环境改变对FL中ENI的影响，我们分析了501例接受利妥昔单抗为基础治疗的新诊断FL患者的临床特征，并分别对403例和175例患者进行了DNA和RNA测序。

结果：在120例（24%）患者中观察到多部位ENI，且与晚期Ann Arbor分期、血红蛋白降低、乳酸脱氢酶升高、β-2微球蛋白升高、淋巴结受累≥5个部位、淋巴结>6 cm以及2年内疾病进展（POD24）高风险显著相关。KMT2D、CREBBP、CARD11和STAT6突变增加，以及免疫相关通路下调和脂质代谢改变，与多部位ENI相关。在利妥昔单抗联合化疗（R-chemo）队列（n=344）中，骨髓、肺、肝、骨骼和肾脏/肾上腺受累是无进展生存期（PFS）的不利预测因子，其中肝和肾脏/肾上腺受累是总生存期（OS）的不利预测因子。然而，在利妥昔单抗联合来那度胺免疫治疗（R2）队列（n=157）中，没有任何ENI部位在PFS和OS方面显示出显著差异。

结论：R2治疗可以克服FL中多部位ENI对R-chemo治疗的负面预后影响。更好地理解多部位ENI的生物学行为可能为未来基于机制的FL治疗提供潜在的临床依据。

### 第二部分 AI 大师评价

本研究系统探讨了滤泡性淋巴瘤结外受累的分子机制和临床意义，具有重要的创新价值。研究通过501例患者的大规模队列分析，结合DNA和RNA测序技术，首次揭示了KMT2D、CREBBP等关键基因突变与多部位结外受累的关联，并发现免疫通路下调和脂质代谢改变在疾病进展中的作用。特别值得注意的是，研究发现R2免疫治疗方案能够有效克服传统化疗中结外受累的负面预后影响，这为临床治疗策略选择提供了重要依据。研究的局限性在于样本量虽大但RNA测序样本相对较少，且为回顾性研究设计，未来需要前瞻性研究进一步验证这些发现。

---

## 8. 基于结构预测揭示抗BCMA抗体与BCMA及可溶性BCMA结合模式的差异

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136753](https://pubmed.ncbi.nlm.nih.gov/41136753)
**期刊：** Leukemia
**PMID：** 41136753
**DOI：** 10.1038/s41375-025-02792-3

### 第一部分 原文与翻译

**英文原标题：** Structure-based prediction reveals a difference in the binding mode of anti-BCMA antibodies to BCMA and soluble BCMA.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究采用基于结构预测的方法，深入探讨了抗BCMA抗体与膜结合型BCMA及可溶性BCMA在结合模式上的差异。研究揭示了不同形式BCMA靶点与抗体相互作用的关键结构特征，这对于理解抗体药物作用机制具有重要意义。该发现为优化抗BCMA抗体疗法提供了重要的理论基础，特别是在多发性骨髓瘤等血液肿瘤治疗中，有助于开发更具选择性和有效性的靶向治疗策略。然而，由于缺乏实验验证数据，该预测结果的可靠性仍需进一步证实。

---

## 9. 肺非典型类癌和大细胞神经内分泌癌的数字免疫表型分析识别出具有特定肿瘤免疫微环境特征的三种亚型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136735](https://pubmed.ncbi.nlm.nih.gov/41136735)
**期刊：** Endocrine pathology
**PMID：** 41136735
**DOI：** 10.1007/s12022-025-09886-9

### 第一部分 原文与翻译

**英文原标题：** Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features.

**英文摘要原文：**
Atypical carcinoids (ACs) and large cell neuroendocrine carcinomas (LCNECs) are defined by the WHO as intermediate- and high-grade lung neuroendocrine neoplasms, respectively, based on morphological criteria; however, treatment strategies remain debated. Given the emerging role of the tumor microenvironment (TME) and tumor-infiltrating lymphocytes (TILs) in cancer prognosis and therapy response, this study aimed to characterize the immune landscape of ACs and LCNECs comprehensively. Immunohistochemistry for T-cell markers (CD3, CD8), immune checkpoints (PD-1, PD-L1), HLA molecules (HLA-DR, HLA-I), and fibroblasts (α-SMA) was performed on a re-evaluated cohort of 56 ACs and 104 LCNECs. Digital image analysis quantified intra-tumor (iTILs) and stromal (sTILs) CD3 and CD8 TILs in the whole slide and in specific tumor regions (invasive margin [IM] and central tumor [CT]). LCNECs exhibited significantly higher stromal T-cell infiltration, immune checkpoint expression, and HLA compared to ACs (p < 0.001), while α-SMA was more prominent in ACs. No ACs showed PD-L1 tumor expression. Digital quantification confirmed greater iTILs and sTILs in LCNECs across all regions, with moderate concordance to manual counts. Interestingly, TIL parameters were higher at the IM than in the CT (p < 0.001). Using Boruta feature selection algorithm, Principal Component Analysis and Hierarchical Clustering, three patient clusters were identified: Cluster 1 (mainly ACs, low TILs, favorable prognosis), Cluster 2 (mixed histology, intermediate TILs, moderate prognosis), and Cluster 3 (mostly LCNECs, high TILs, poor prognosis), with distinct TME marker profiles. PD-L1 tumor expression was strongly linked to Cluster 3. These findings suggest that ACs and LCNECs may be stratified into three distinct immune clusters, highlighting the heterogeneity of their tumor microenvironment and providing a rationale for further translational studies.

**中文摘要译文：**
根据形态学标准，世界卫生组织将非典型类癌（ACs）和大细胞神经内分泌癌（LCNECs）分别定义为中级别和高级别肺神经内分泌肿瘤；然而，治疗策略仍存在争议。鉴于肿瘤微环境（TME）和肿瘤浸润淋巴细胞（TILs）在癌症预后和治疗反应中的新兴作用，本研究旨在全面表征ACs和LCNECs的免疫景观。对重新评估的56例ACs和104例LCNECs队列进行了T细胞标志物（CD3、CD8）、免疫检查点（PD-1、PD-L1）、HLA分子（HLA-DR、HLA-I）和成纤维细胞（α-SMA）的免疫组织化学检测。数字图像分析量化了整张切片和特定肿瘤区域（侵袭边缘[IM]和中央肿瘤[CT]）中的肿瘤内（iTILs）和间质（sTILs）CD3和CD8 TILs。与ACs相比，LCNECs表现出显著更高的间质T细胞浸润、免疫检查点表达和HLA（p < 0.001），而α-SMA在ACs中更为显著。没有ACs显示PD-L1肿瘤表达。数字量化证实了LCNECs在所有区域中具有更高的iTILs和sTILs，与人工计数具有中等程度的一致性。有趣的是，IM处的TIL参数高于CT处（p < 0.001）。使用Boruta特征选择算法、主成分分析和层次聚类，确定了三个患者聚类：聚类1（主要为ACs，低TILs，预后良好）、聚类2（混合组织学，中等TILs，预后中等）和聚类3（主要为LCNECs，高TILs，预后不良），具有不同的TME标志物谱。PD-L1肿瘤表达与聚类3密切相关。这些发现表明，ACs和LCNECs可能被分为三个不同的免疫聚类，突出了其肿瘤微环境的异质性，并为进一步的转化研究提供了理论基础。

### 第二部分 AI 大师评价

本研究通过数字免疫表型分析深入揭示了肺神经内分泌肿瘤的免疫微环境异质性。研究团队采用免疫组织化学和数字图像分析技术，系统比较了56例非典型类癌和104例大细胞神经内分泌癌的免疫特征，创新性地识别出三个具有不同预后特征的免疫亚型。该研究的核心价值在于突破了传统形态学分类的局限，为这类罕见肿瘤的精准免疫治疗提供了重要依据。然而，研究仍受限于回顾性设计，未来需要前瞻性验证这些免疫分型的临床指导价值。

---

## 10. 艾滋病研究如何推动多种疾病领域的健康创新

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136629](https://pubmed.ncbi.nlm.nih.gov/41136629)
**期刊：** Nature medicine
**PMID：** 41136629
**DOI：** 10.1038/s41591-025-04019-5

### 第一部分 原文与翻译

**英文原标题：** How HIV research drives health innovation in multiple diseases.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于艾滋病研究对多疾病领域健康创新的推动作用。通过系统回顾和分析艾滋病研究的历史发展轨迹，揭示了其在基础科学研究、药物开发和治疗策略方面的突破性成果如何转化应用于其他疾病领域。该研究具有重要的科学价值和现实意义，不仅阐明了跨疾病研究协同创新的机制，还为未来多学科交叉研究提供了理论框架和实践指导。然而，由于缺乏具体的研究方法和数据支撑，其结论的实证基础有待进一步验证。

---

## 11. DARPP-32是M2型巨噬细胞极化的新型调节因子：通过直接结合并抑制酪氨酸磷酸酶SHP-1来维持STAT6磷酸化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136558](https://pubmed.ncbi.nlm.nih.gov/41136558)
**期刊：** Oncogene
**PMID：** 41136558
**DOI：** 10.1038/s41388-025-03610-x

### 第一部分 原文与翻译

**英文原标题：** DARPP-32 is a novel regulator of M2-macrophage polarization: Sustains STAT6 phosphorylation by directly binding and inhibiting tyrosine phosphatase SHP-1.

**英文摘要原文：**
Identifying novel factors driving M2-macrophage polarization may help understand immune modulation in cancers. We identified DARPP-32, a protein phosphatase inhibitor, to be significantly upregulated in FBXW7 knock out THP-1 spontaneously polarized to M2 macrophages. DARPP-32 levels remarkably increased in macrophages treated with different M2-inducers while it copiously decreased upon treatment with M1 inducer Lipopolysaccharide/IFN-γ. Intriguingly, mere DARPP-32 over-expression robustly promoted M2-macrophage polarization in different macrophage cell lines and murine primary bone marrow derived macrophages, even without any external stimulation. Conversely, DARPP-32 depletion hampered the IL-4 induced M2-polarization. Strikingly, DARPP-32 overexpression also dampened the classical M1 activation profile of macrophages in response to LPS, skewing their function towards more anti-inflammatory M2-like phenotype. Mechanistically, Thr34-phosphorylated DARPP-32 positively regulates JAK1-STAT6 signalling by directly binding and inhibiting protein tyrosine phosphatase SHP-1, a key regulator of immune cell signalling and macrophage activation. In line with increased DARPP-32 levels in M2-polarized macrophages, which are often tumor-associated macrophages, we also observed markedly increased DARPP-32 levels in tumor-infiltrating macrophages within primary TNBC tumors. We also observed an increase in DARPP-32 levels in macrophages co-cultured with tumor cells. This is first comprehensive study that demonstrate a novel function of DARPP-32 as a driver/regulator of macrophage polarization towards anti-inflammatory M2-phenotype.

**中文摘要译文：**
识别驱动M2型巨噬细胞极化的新因子可能有助于理解癌症中的免疫调节。我们发现DARPP-32（一种蛋白磷酸酶抑制剂）在FBXW7敲除的THP-1细胞自发极化至M2巨噬细胞时显著上调。在不同M2诱导剂处理的巨噬细胞中，DARPP-32水平显著增加，而在M1诱导剂脂多糖/IFN-γ处理时其水平大量减少。有趣的是，仅DARPP-32的过表达就能在不同巨噬细胞系和鼠源原代骨髓来源巨噬细胞中强力促进M2型巨噬细胞极化，甚至无需任何外部刺激。相反，DARPP-32的耗竭阻碍了IL-4诱导的M2极化。引人注目的是，DARPP-32过表达也抑制了巨噬细胞对LPS反应的经典M1活化特征，使其功能偏向更具抗炎性的M2样表型。机制上，Thr34磷酸化的DARPP-32通过直接结合并抑制蛋白酪氨酸磷酸酶SHP-1（免疫细胞信号传导和巨噬细胞活化的关键调节因子）来正向调节JAK1-STAT6信号通路。与M2极化巨噬细胞（通常是肿瘤相关巨噬细胞）中DARPP-32水平升高一致，我们在原发性三阴性乳腺癌肿瘤内的肿瘤浸润巨噬细胞中也观察到DARPP-32水平显著增加。我们还在与肿瘤细胞共培养的巨噬细胞中观察到DARPP-32水平的增加。这是首次全面研究证明DARPP-32作为巨噬细胞向抗炎性M2表型极化的驱动/调节因子的新功能。

### 第二部分 AI 大师评价

本研究首次系统揭示了DARPP-32作为M2型巨噬细胞极化的关键调节因子的新功能。通过基因敲除、过表达和共培养等多种实验方法，研究发现DARPP-32不仅能够独立驱动巨噬细胞向M2表型极化，还能抑制M1活化特征，其机制是通过直接结合并抑制SHP-1磷酸酶来维持STAT6磷酸化。这一发现具有重要的创新性，为理解肿瘤微环境中免疫抑制机制提供了新视角，特别是DARPP-32在肿瘤浸润巨噬细胞中的高表达提示其在肿瘤免疫逃逸中可能发挥重要作用。该研究为开发针对肿瘤相关巨噬细胞的免疫治疗策略提供了新的分子靶点，但研究主要基于体外实验，其临床转化价值仍需进一步体内验证。

---

## 12. 癌症相关成纤维细胞分泌的细胞因子CCL2通过ERK1/2信号通路增强胶质母细胞瘤对替莫唑胺的耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136557](https://pubmed.ncbi.nlm.nih.gov/41136557)
**期刊：** Oncogene
**PMID：** 41136557
**DOI：** 10.1038/s41388-025-03601-y

### 第一部分 原文与翻译

**英文原标题：** Cytokine CCL2 secreted by cancer-associated fibroblasts augments temozolomide resistance in glioblastoma through ERK1/2 signaling.

**英文摘要原文：**
The intricate tumor microenvironment largely influences chemoresistance in glioblastoma. Cancer-associated fibroblasts (CAFs) that modulate tumor progression have recently been identified as non-tumor stromal cells within the glioblastoma microenvironment. It remains unclear whether CAFs play a role in conferring chemoresistance to glioblastoma. The effects and mechanisms of CAFs on glioblastoma cells under temozolomide (TMZ) treatment are investigated by a series of patient-derived CAFs, orthotopic xenograft mouse models, and glioblastoma organoids (GBOs). Patient-derived cells have a transcriptomic and biomolecular profile of CAFs. CAFs promote temozolomide resistance in glioblastoma in vitro; these findings are consistent with results from intracranial tumor xenografts and GBO models. Mechanistically, CAFs express and secrete a significantly higher C-C motif chemokine ligand 2 (CCL2), which selectively enhances the activation of the ERK1/2 signaling in glioblastoma cells. Pharmacologically disrupting the CCL2-CCR2 axis or MEK1/2-ERK1/2 pathway effectively restores the therapeutic efficacy of temozolomide in glioblastoma cells and patient-derived GBOs. The decreased phosphor-ERK1/2 expression induced by trametinib treatment is also observed in glioblastoma cells following the CCL2-CCR2 axis inhibition. The present study suggests that targeting the CCL2/CCR2/ERK1/2 pathway may help overcome chemoresistance in glioblastomas caused by CAFs.

**中文摘要译文：**
复杂的肿瘤微环境在很大程度上影响胶质母细胞瘤的化疗耐药性。调节肿瘤进展的癌症相关成纤维细胞（CAFs）最近被确认为胶质母细胞瘤微环境中的非肿瘤基质细胞。目前尚不清楚CAFs是否在赋予胶质母细胞瘤化疗耐药性中发挥作用。通过一系列患者来源的CAFs、原位异种移植小鼠模型和胶质母细胞瘤类器官（GBOs），研究了在替莫唑胺（TMZ）治疗下CAFs对胶质母细胞瘤细胞的影响及其机制。患者来源的细胞具有CAFs的转录组学和生物分子特征。CAFs在体外促进胶质母细胞瘤对替莫唑胺的耐药性；这些发现与颅内肿瘤异种移植和GBO模型的结果一致。从机制上讲，CAFs表达并分泌显著更高的C-C基序趋化因子配体2（CCL2），该因子选择性地增强胶质母细胞瘤细胞中ERK1/2信号的激活。药理学上破坏CCL2-CCR2轴或MEK1/2-ERK1/2通路可有效恢复替莫唑胺在胶质母细胞瘤细胞和患者来源的GBOs中的治疗效果。在抑制CCL2-CCR2轴后，胶质母细胞瘤细胞中也观察到曲美替尼治疗诱导的磷酸化ERK1/2表达降低。本研究提示，靶向CCL2/CCR2/ERK1/2通路可能有助于克服由CAFs引起的胶质母细胞瘤化疗耐药性。

### 第二部分 AI 大师评价

本研究深入探讨了癌症相关成纤维细胞（CAFs）在胶质母细胞瘤化疗耐药中的关键作用，具有重要的创新价值。研究采用患者来源的CAFs、原位异种移植模型和胶质母细胞瘤类器官等多层次实验体系，系统揭示了CAFs通过分泌CCL2激活ERK1/2信号通路，从而增强胶质母细胞瘤对替莫唑胺耐药性的分子机制。关键发现表明，靶向CCL2-CCR2轴或MEK1/2-ERK1/2通路可有效逆转这种耐药性，为克服胶质母细胞瘤治疗瓶颈提供了新的策略。该研究不仅深化了对肿瘤微环境介导化疗耐药机制的理解，更提出了具有转化潜力的治疗靶点，对改善胶质母细胞瘤患者预后具有重要的临床意义。

---

## 13. Apaf1大分子瞬时组装体构成细胞中的凋亡小体

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136486](https://pubmed.ncbi.nlm.nih.gov/41136486)
**期刊：** Nature communications
**PMID：** 41136486
**DOI：** 10.1038/s41467-025-64478-9

### 第一部分 原文与翻译

**英文原标题：** Large transient assemblies of Apaf1 constitute the apoptosome in cells.

**英文摘要原文：**
Upon cell death signals, the apoptotic protease-activating factor Apaf1 and cytochrome c interact to form the apoptosome complex. The apoptosome is crucial for mitochondrial apoptosis, as it activates caspases that dismantle the cell. However, the in vivo assembly mechanism and appearance of the apoptosome remain unclear. We show that upon onset of apoptosis, Apaf1 molecules accumulate into multiple foci per cell. Disassembly of the foci correlates with cell survival. Structurally, Apaf1 foci resemble organelle-sized, cloud-like assemblies. They form through specific interactions with cytochrome c, contain caspase-9, and depend on procaspase-9 expression for their formation. We propose that Apaf1 foci correspond to the apoptosome in cells. Transientness and ultrastructure of Apaf1 foci suggest that the dynamic spatiotemporal organisation of apoptosome components regulates progression of apoptosis.

**中文摘要译文：**
在细胞死亡信号作用下，凋亡蛋白酶激活因子Apaf1与细胞色素c相互作用形成凋亡小体复合物。凋亡小体对线粒体凋亡至关重要，因为它激活了分解细胞的caspase酶。然而，凋亡小体的体内组装机制和形态仍然不清楚。我们发现，在凋亡启动时，Apaf1分子在每个细胞中积累形成多个焦点。这些焦点的解聚与细胞存活相关。从结构上看，Apaf1焦点类似于细胞器大小的云状组装体。它们通过与细胞色素c的特异性相互作用形成，含有caspase-9，并且其形成依赖于procaspase-9的表达。我们提出Apaf1焦点对应于细胞中的凋亡小体。Apaf1焦点的瞬时性和超微结构表明，凋亡小体组分的动态时空组织调控着凋亡进程。

### 第二部分 AI 大师评价

本研究通过活细胞成像技术揭示了凋亡小体的真实形态和动态组装过程，填补了细胞凋亡领域的重要知识空白。研究发现Apaf1在凋亡过程中形成多个瞬时性的云状组装体，这些焦点结构依赖于细胞色素c和procaspase-9的表达，并直接调控凋亡进程。该研究的创新性在于首次在活细胞中观察到凋亡小体的真实形态，挑战了传统的静态结构模型，提出了动态组装调控的新机制。这一发现对理解细胞死亡调控机制具有重要理论价值，并为开发靶向凋亡通路的疾病治疗策略提供了新的思路。然而，研究主要基于体外细胞模型，其生理相关性仍需在更复杂的生物系统中进一步验证。

---

## 14. 白质高信号进展的独特时空模式

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136463](https://pubmed.ncbi.nlm.nih.gov/41136463)
**期刊：** Nature communications
**PMID：** 41136463
**DOI：** 10.1038/s41467-025-64704-4

### 第一部分 原文与翻译

**英文原标题：** Distinct spatiotemporal patterns of white matter hyperintensity progression.

**英文摘要原文：**
White matter hyperintensity, a key imaging biomarker for brain health, has prognostic implications for stroke. Using a multicenter MRI dataset of 9179 stroke patients plus the UK Biobank (n = 36,210 low/high risk controls), we employ Subtype and Stage Inference modeling and identify three distinct white matter hyperintensity progression subtypes: fronto-parietal, radial, and temporo-occipital. Longitudinal validation confirms classification stability. The fronto-parietal subtype shows delayed onset and more hypertension, while the temporo-occipital subtype has more atrial fibrillation and coronary heart disease. The fronto-parietal and radial subtypes are linked to small vessel stroke, while the temporo-occipital subtype is linked to cardioembolism. The fronto-parietal subtype has higher 1-year ischemic stroke recurrence, while the temporo-occipital subtype shows a higher incidence of early neurological deterioration by symptomatic hemorrhagic transformation and worse 3-month outcomes. Beyond capturing progression, demographics, and vascular risks, and improving post-stroke outcome prediction, this subtyping-staging model also holds potential for stroke prediction.

**中文摘要译文：**
白质高信号作为脑健康的关键影像学生物标志物，对卒中具有预后意义。利用9179名卒中患者的多中心MRI数据集加上英国生物样本库（n=36,210低/高风险对照），我们采用亚型和阶段推断模型，识别出三种不同的白质高信号进展亚型：额顶叶型、放射型和颞枕叶型。纵向验证证实了分类的稳定性。额顶叶亚型显示较晚发病和更多高血压，而颞枕叶亚型则有更多房颤和冠心病。额顶叶和放射亚型与小血管卒中相关，而颞枕叶亚型与心源性栓塞相关。额顶叶亚型具有较高的1年缺血性卒中复发率，而颞枕叶亚型则显示因症状性出血转化导致的早期神经功能恶化发生率较高，且3个月预后更差。除了捕捉进展、人口统计学和血管风险因素，并改善卒中后结局预测外，这种分型-分期模型还具有卒中预测的潜力。

### 第二部分 AI 大师评价

本研究通过亚型和阶段推断模型，在大规模卒中患者队列中首次系统识别了白质高信号进展的三种时空模式亚型。研究创新性地将影像学进展模式与特定血管危险因素、卒中病因及临床预后建立了明确的关联，为卒中精准医学提供了重要依据。该模型的建立不仅显著提升了卒中后结局预测的准确性，更开创性地展示了在卒中预测领域的应用潜力。然而，研究主要基于回顾性数据，未来需要前瞻性研究进一步验证这些亚型在临床实践中的指导价值。

---

## 15. 模态投影通用模型：实现全面全身医学影像分割

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136445](https://pubmed.ncbi.nlm.nih.gov/41136445)
**期刊：** Nature communications
**PMID：** 41136445
**DOI：** 10.1038/s41467-025-64469-w

### 第一部分 原文与翻译

**英文原标题：** Modality-projection universal model for comprehensive full-body medical imaging segmentation.

**英文摘要原文：**
The integration of deep learning in medical imaging has significantly advanced diagnostic, therapeutic, and research outcomes. However, applying universal models across multiple modalities remains challenging due to inherent inter-modality variability. Here we present the Modality Projection Universal Model (MPUM), trained on 861 subjects, which dynamically adapts to diverse imaging modalities through a modality-projection strategy. MPUM achieves state-of-the-art, whole-body organ segmentation, providing rapid localization for computer-aided diagnosis and precise anatomical quantification to support clinical decision-making. A controller-based convolutional layer further enables saliency map visualization, enhancing model interpretability for clinical use. Beyond segmentation, MPUM reveals metabolic correlations along the brain-body axis and between distinct brain regions, providing insights into systemic and physiological interactions from a whole-body perspective. Here we show that this universal framework accelerates diagnosis, facilitates large-scale imaging analysis, and bridges anatomical and metabolic information, enabling discovery of cross-organ disease mechanisms and advancing integrative brain-body research.

**中文摘要译文：**
深度学习在医学影像中的整合显著推进了诊断、治疗和研究结果。然而，由于固有的模态间变异性，在多种模态间应用通用模型仍然具有挑战性。在此，我们提出了模态投影通用模型（MPUM），该模型基于861名受试者进行训练，通过模态投影策略动态适应不同的成像模态。MPUM实现了最先进的全身器官分割，为计算机辅助诊断提供快速定位，并为支持临床决策提供精确的解剖量化。基于控制器的卷积层进一步实现了显著性图可视化，增强了模型在临床应用中的可解释性。除了分割功能外，MPUM揭示了沿脑-体轴线和不同脑区之间的代谢相关性，从全身视角提供了对系统和生理相互作用的见解。在此我们证明，这一通用框架加速了诊断，促进了大规模影像分析，并桥接了解剖和代谢信息，使得跨器官疾病机制的发现成为可能，并推进了整合性脑-体研究。

### 第二部分 AI 大师评价

本研究开发了一种创新的模态投影通用模型（MPUM），旨在解决多模态医学影像分割中的技术挑战。通过基于861名受试者的训练数据和模态投影策略，该模型实现了动态适应不同成像模态的能力，在全身器官分割方面达到最先进水平。其核心创新在于不仅提供精确的解剖分割，还通过显著性图可视化增强模型可解释性，并首次从全身视角揭示了脑-体轴线和脑区间的代谢相关性。这一框架具有重要的临床价值，能够加速诊断过程，支持大规模影像分析，并为理解跨器官疾病机制提供了新的研究途径，推动了整合性脑-体研究的发展。然而，该模型在更广泛临床应用中的泛化能力仍需进一步验证。

---

## 16. 力学生物学优化的非吸收性人工骨用于患者匹配的支架引导骨再生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136443](https://pubmed.ncbi.nlm.nih.gov/41136443)
**期刊：** Nature communications
**PMID：** 41136443
**DOI：** 10.1038/s41467-025-64466-z

### 第一部分 原文与翻译

**英文原标题：** Mechanobiologically-optimized non-resorbable artificial bone for patient-matched scaffold-guided bone regeneration.

**英文摘要原文：**
Scaffold-guided bone regeneration is poised to revolutionize the management of critical-sized bone defects. However, translation into clinical practice has been hampered by the focus on bioresorbable scaffolds where the rate of degradation needs to match the rate of bone formation and metal plates are required to overcome their mechanical limitations. Metal plates are problematic because they cause stress shielding and X-ray perturbation, increasing the likelihood of hardware failure and interfering with post-operative radiotherapy and imaging. Segmental defects of the mandible are challenging due to high tensile and shear stresses encountered during mastication, with the ovine mandible especially vexing because of the high repetitive loads. Here we show long-term reconstruction of ovine segmental mandibulectomy defects using a permanent, patient-matched, numerically optimized, 3D-printed, thermally toughened, plasma-treated, and laser-sintered polyetherketone gyroid scaffold housing a resorbable ceramic lattice infused with a stem cell laden hydrogel serving as an osteoinductive reservoir of calcium. The durable clinical performance observed indicates a translatable alternative to traditional reconstruction using bone grafts with metal plate fixation.

**中文摘要译文：**
支架引导骨再生有望彻底改变临界尺寸骨缺损的治疗。然而，由于主要关注生物可吸收支架，其向临床实践的转化受到阻碍，因为这类支架的降解速率需要与骨形成速率相匹配，并且需要金属板来克服其力学局限性。金属板存在问题，因为它们会引起应力遮挡和X射线干扰，增加硬件失效的可能性，并干扰术后放疗和成像。下颌骨节段性缺损由于咀嚼过程中遇到的高拉伸和剪切应力而具有挑战性，绵羊下颌骨尤其棘手，因为其承受高重复性负荷。在此，我们展示了使用永久性、患者匹配、数值优化、3D打印、热韧化、等离子体处理和激光烧结的聚醚酮螺旋支架，该支架内含有可吸收陶瓷晶格，该晶格注入载有干细胞的水凝胶，作为钙的骨诱导储库，实现了绵羊下颌骨节段性切除缺损的长期重建。观察到的持久临床性能表明，这是一种可转化为传统使用骨移植加金属板固定重建的替代方案。

### 第二部分 AI 大师评价

本研究开发了一种力学生物学优化的非吸收性人工骨支架，旨在解决传统骨缺损修复中的关键挑战。研究团队采用多学科方法，结合患者匹配设计、数值优化、3D打印技术和先进的材料处理工艺，创建了聚醚酮螺旋支架系统。该支架的创新之处在于将永久性结构与非吸收性陶瓷晶格和干细胞水凝胶相结合，既提供了持久的力学支撑，又保持了骨诱导活性。这项研究在绵羊下颌骨模型中的成功应用，为临床上处理复杂骨缺损提供了一种有前景的替代方案，避免了传统金属板带来的应力遮挡和影像干扰问题，具有重要的临床转化价值。

---

## 17. 利用异质同步学习解决分布式医学影像中的数据异质性问题

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136442](https://pubmed.ncbi.nlm.nih.gov/41136442)
**期刊：** Nature communications
**PMID：** 41136442
**DOI：** 10.1038/s41467-025-64459-y

### 第一部分 原文与翻译

**英文原标题：** Addressing data heterogeneity in distributed medical imaging with heterosync learning.

**英文摘要原文：**
Data heterogeneity critically limits distributed artificial intelligence (AI) in medical imaging. We propose HeteroSync Learning (HSL), a privacy-preserving framework that addresses heterogeneity through: (1) Shared Anchor Task (SAT) for cross-node representation alignment, and (2) an Auxiliary Learning Architecture coordinating SAT with local primary tasks. Validated via large-scale simulations (feature/label/quantity/combined heterogeneity) and a real-world multi-center thyroid cancer study, HSL outperforms local learning, 12 benchmark methods (FedAvg, FedProx, SplitAVG, FedRCL, FedCOME, etc.), and foundation models (e.g., CLIP) by better stability and up to 40% in area under the curve (AUC), matching central learning performance. HSL achieves 0.846 AUC on the out-of-distribution pediatric thyroid cancer data (outperforming others by 5.1-28.2%), demonstrating superior generalization. Visualizations confirm HSL successfully homogenizes heterogeneous distributions. This work provides an effective solution for distributed medical AI, enabling equitable collaboration across institutions and advancing healthcare AI democratization.

**中文摘要译文：**
数据异质性严重限制了医学影像中分布式人工智能的发展。我们提出了异质同步学习（HSL），这是一个保护隐私的框架，通过以下方式解决异质性问题：（1）共享锚定任务（SAT）用于跨节点表征对齐，以及（2）辅助学习架构协调SAT与本地主要任务。通过大规模模拟（特征/标签/数量/组合异质性）和真实世界多中心甲状腺癌研究验证，HSL在稳定性和曲线下面积（AUC）方面优于本地学习、12种基准方法（FedAvg、FedProx、SplitAVG、FedRCL、FedCOME等）以及基础模型（如CLIP），AUC提升高达40%，与中心化学习性能相当。HSL在分布外儿科甲状腺癌数据上达到0.846的AUC（比其他方法高出5.1-28.2%），展示了卓越的泛化能力。可视化结果证实HSL成功地将异质分布同质化。这项工作为分布式医学AI提供了有效的解决方案，实现了跨机构的公平协作，并推动了医疗AI民主化进程。

### 第二部分 AI 大师评价

本研究旨在解决分布式医学影像AI中数据异质性这一关键瓶颈问题。作者提出的异质同步学习（HSL）框架创新性地结合了共享锚定任务和辅助学习架构，在保护数据隐私的同时实现了跨机构表征对齐。研究通过大规模模拟和真实世界多中心甲状腺癌研究验证了方法的有效性，在多种异质场景下显著优于现有12种基准方法，特别是在分布外儿科数据上表现出卓越的泛化能力。该研究为分布式医疗AI协作提供了实用解决方案，有望推动医疗AI的公平发展和广泛应用，但未来仍需在更多疾病类型和临床场景中验证其普适性。

---

## 18. HIV-1整合酶寡聚体结构揭示其在整合体组装和RNA结合中的功能可塑性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136407](https://pubmed.ncbi.nlm.nih.gov/41136407)
**期刊：** Nature communications
**PMID：** 41136407
**DOI：** 10.1038/s41467-025-64479-8

### 第一部分 原文与翻译

**英文原标题：** Oligomeric HIV-1 integrase structures reveal functional plasticity for intasome assembly and RNA binding.

**英文摘要原文：**
Integrase (IN) performs dual essential roles during HIV-1 replication. During ingress, IN functions within an oligomeric "intasome" assembly to catalyze viral DNA integration into host chromatin. During late stages of infection, tetrameric IN binds viral RNA and orchestrates the condensation of ribonucleoprotein complexes into the capsid core. The molecular architectures of HIV-1 IN assemblies that mediate these distinct events remain unknown. Furthermore, the IN tetramer is an important antiviral target for investigational allosteric IN inhibitors. Here, we determined cryo-EM structures of wildtype HIV-1 IN tetramers and intasome hexadecamers. Our structures unveil a remarkable plasticity that leverages IN C-terminal domains and abutting linkers to assemble functionally distinct oligomeric forms. Alteration of a newly recognized conserved interface revealed that both IN functions track with tetramerization in vitro and during HIV-1 infection. Collectively, our findings reveal how IN plasticity orchestrates its diverse molecular functions and suggest a working model for IN-viral RNA binding. Moreover, our structure of the IN tetramer provides atomic blueprints for the rational development of improved allosteric inhibitors.

**中文摘要译文：**
整合酶（IN）在HIV-1复制过程中发挥双重关键作用。在病毒进入阶段，IN在寡聚"整合体"组装中发挥作用，催化病毒DNA整合到宿主染色质中。在感染晚期，四聚体IN结合病毒RNA，并协调核糖核蛋白复合物凝聚成衣壳核心。介导这些不同事件的HIV-1 IN组装的分子结构仍然未知。此外，IN四聚体是研究性变构IN抑制剂的重要抗病毒靶点。在此，我们确定了野生型HIV-1 IN四聚体和整合体十六聚体的冷冻电镜结构。我们的结构揭示了一种显著的可塑性，利用IN C末端结构域和相邻连接子来组装功能不同的寡聚形式。对新识别的保守界面的改变显示，IN的两种功能在体外和HIV-1感染期间都与四聚化相关。总的来说，我们的发现揭示了IN可塑性如何协调其多样化的分子功能，并提出了IN-病毒RNA结合的工作模型。此外，我们的IN四聚体结构为合理开发改进的变构抑制剂提供了原子蓝图。

### 第二部分 AI 大师评价

本研究通过冷冻电镜技术解析了HIV-1整合酶四聚体和整合体十六聚体的高分辨率结构，揭示了整合酶通过C末端结构域的可塑性组装机制实现不同功能的分子基础。研究创新性地发现了一个新的保守界面，证明整合酶的四聚化与其在病毒DNA整合和RNA包装中的双重功能密切相关。这项研究不仅为理解HIV-1复制机制提供了重要的结构生物学基础，更重要的是为开发新型变构抑制剂提供了精确的原子蓝图，具有重要的抗病毒药物研发价值。虽然研究主要基于体外结构分析，但其发现为后续功能验证和药物设计奠定了坚实基础。

---

## 19. 人胚胎间充质干细胞中EWS::FLI1表达导致转录重编程、DNA损伤修复缺陷和尤文肉瘤形成

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136396](https://pubmed.ncbi.nlm.nih.gov/41136396)
**期刊：** Nature communications
**PMID：** 41136396
**DOI：** 10.1038/s41467-025-64475-y

### 第一部分 原文与翻译

**英文原标题：** EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma.

**英文摘要原文：**
Ewing sarcoma (ES) is an aggressive bone and soft tissue neoplasm characterized by EWSR::ETS rearrangements whose cellular origin remains unclear. EWS::FLI1 expression in human pediatric mesenchymal stem cells (MSCs) induces a transcriptional response distinct from that of human adult MSCs, but fails to form tumors. Here we show that EWS::FLI1 expression in human embryonic mesenchymal stem cells (heMSCs) results in the acquisition of an ES transcriptome, with the oncogene not preferentially binding to gene promoters, but to intronic and intergenic microsatellites. In heMSCs, EWS::FLI1 directly regulates the expression of the DNA repair protein BRCA1, although cells expressing EWS::FLI1 show DNA damage. Xenografting of EWS::FLI1-transduced heMSCs results in the formation of tumors expressing characteristic ES markers. In summary, we show that EWS::FLI1 enforces an aberrant transcriptome and solely is able to endow transforming capacity when expressed in undifferentiated, early heMSCs.

**中文摘要译文：**
尤文肉瘤（ES）是一种侵袭性的骨和软组织肿瘤，其特征是EWSR::ETS重排，但其细胞起源仍不清楚。在人儿童间充质干细胞（MSCs）中表达EWS::FLI1会诱导与成人MSCs不同的转录反应，但无法形成肿瘤。本文显示，在人胚胎间充质干细胞（heMSCs）中表达EWS::FLI1会导致获得ES转录组特征，该癌基因不优先结合基因启动子，而是结合内含子和基因间微卫星。在heMSCs中，EWS::FLI1直接调控DNA修复蛋白BRCA1的表达，尽管表达EWS::FLI1的细胞显示出DNA损伤。将EWS::FLI1转导的heMSCs进行异种移植会导致表达特征性ES标志物的肿瘤形成。总之，我们证明EWS::FLI1强制实施异常转录组，并且仅在未分化的早期heMSCs中表达时能够赋予转化能力。

### 第二部分 AI 大师评价

本研究通过在人胚胎间充质干细胞中表达EWS::FLI1癌基因，成功揭示了尤文肉瘤的细胞起源机制。研究创新性地发现该癌基因优先结合内含子和基因间微卫星而非基因启动子，并直接调控DNA修复蛋白BRCA1的表达，同时导致DNA损伤修复缺陷。这一发现不仅阐明了尤文肉瘤发生的分子机制，更重要的是确定了未分化的早期胚胎间充质干细胞是该肿瘤的潜在起源细胞，为理解肿瘤发生和开发靶向治疗提供了重要理论基础。研究局限性在于主要基于体外和动物模型，其临床转化价值仍需进一步验证。

---

## 20. 核内TRiC/CCT伴侣蛋白将减数分裂HORMAD蛋白组装成具备交叉能力的染色体轴

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136395](https://pubmed.ncbi.nlm.nih.gov/41136395)
**期刊：** Nature communications
**PMID：** 41136395
**DOI：** 10.1038/s41467-025-64403-0

### 第一部分 原文与翻译

**英文原标题：** A nuclear TRiC/CCT chaperonin assembles meiotic HORMAD proteins into chromosome axes competent for crossing over.

**英文摘要原文：**
The meiotic chromosome axis organizes chromatin and sets the stage for homolog pairing and recombination. Meiotic HORMA domain proteins (mHORMADs) are conserved axis components that conformationally transform during target binding. In C. elegans, four functionally distinct mHORMADs directly interact, but how binding between them is restricted to axis assembly is unknown. Using a mutation in the mHORMADs that delays axis assembly, we isolated a suppressor mutation in a TRiC (Tailless complex peptide 1 Ring Complex) chaperonin subunit that restored mHORMAD localization. CCT-4 associates with meiotic chromatin and forms in vivo complexes with mHORMADs, while germline disruption of TRiC results in axis defects, indicating a nuclear function for TRiC alongside meiotic chromosomes. We propose that chromosome-associated TRiC locally folds mHORMADs into the binding-competent conformation required for axis morphogenesis. More broadly, our results support the model that spatially-restricted folding by TRiC/CCT is a mechanism of controlling the assembly of multimeric complexes that function in tightly co-ordinated events.

**中文摘要译文：**
减数分裂染色体轴组织染色质并为同源染色体配对和重组奠定基础。减数分裂HORMA结构域蛋白(mHORMADs)是保守的染色体轴组分，在靶标结合过程中会发生构象转变。在秀丽隐杆线虫中，四个功能不同的mHORMADs直接相互作用，但它们之间的结合如何被限制在染色体轴组装中尚不清楚。利用一个延迟染色体轴组装的mHORMADs突变，我们分离出了一个TRiC(无尾复合肽1环复合物)伴侣蛋白亚基的抑制突变，该突变恢复了mHORMAD的定位。CCT-4与减数分裂染色质相关联，并与mHORMADs形成体内复合物，而TRiC的生殖系破坏会导致染色体轴缺陷，表明TRiC在减数分裂染色体旁具有核内功能。我们提出染色体相关的TRiC局部折叠mHORMADs，使其形成染色体轴形态发生所需的结合能力构象。更广泛地说，我们的结果支持TRiC/CCT通过空间限制性折叠来控制多聚复合物组装的模型，这些复合物在紧密协调的事件中发挥作用。

### 第二部分 AI 大师评价

本研究通过遗传筛选和分子生物学方法，揭示了TRiC/CCT伴侣蛋白在减数分裂染色体轴组装中的关键作用。研究团队利用秀丽隐杆线虫模型，发现核内TRiC能够局部折叠mHORMADs蛋白，使其获得正确的构象以促进染色体轴的形成。这一发现具有重要的创新性，首次证明了伴侣蛋白在细胞核内对多蛋白复合物组装的时空调控机制。该研究不仅深化了我们对减数分裂分子机制的理解，也为其他需要精确时空调控的细胞过程提供了新的研究范式。然而，研究主要基于线虫模型，在哺乳动物系统中的保守性仍需进一步验证。

---

## 21. 基于microRNA CRISPR筛选揭示microRNA-483-3p在前列腺癌细胞中作为凋亡调节因子的作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136394](https://pubmed.ncbi.nlm.nih.gov/41136394)
**期刊：** Cell death & disease
**PMID：** 41136394
**DOI：** 10.1038/s41419-025-08098-7

### 第一部分 原文与翻译

**英文原标题：** A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells.

**英文摘要原文：**
The development of traditional protein-targeted cancer therapies is a slow and arduous process, often taking years or even decades. In contrast, RNA-based therapies targeting crucial microRNA (miRNA) offer a faster alternative due to the sequence-specific nature of miRNA inhibitor binding. This, combined with the capacity of individual miRNA to influence multiple cellular pathways, makes these small RNA attractive targets for cancer therapy. While miRNA are known to be dysregulated in prostate cancer (PCa), identifying their individual contributions to disease progression and the identification of therapeutically actionable miRNA targets in PCa has been challenging due to limited profiling and lack of screening tools. To address this need, we developed miRKOv2, a miRNA-only CRISPR knockout library enabling systematic, genome-wide loss-of-function screens to identify miRNA essential for PCa cell survival. Our screens uncovered 70 potential essential miRNA candidates, with miR-483 demonstrating the most significant impact on PCa cell viability. Functional characterization revealed that miR-483 disruption potentiated apoptosis in PCa cell lines. Mechanistically, we uncovered a novel regulatory axis wherein miR-483-3p directly modulates a BCLAF1/PUMA/BAK1 apoptotic signaling network, highlighting its critical role in maintaining PCa cell survival. Our findings provide novel insights into the complex regulatory role of miRNA in PCa progression and offer a potential therapeutic strategy for targeting miRNA-mediated pathways in metastatic disease.

**中文摘要译文：**
传统蛋白质靶向癌症疗法的开发是一个缓慢而艰难的过程，通常需要数年甚至数十年时间。相比之下，针对关键microRNA（miRNA）的RNA疗法由于miRNA抑制剂结合的序列特异性，提供了一个更快的替代方案。这一点，加上单个miRNA能够影响多个细胞通路的能力，使得这些小RNA成为癌症治疗的有吸引力的靶点。虽然已知miRNA在前列腺癌（PCa）中失调，但由于有限的表达谱分析和缺乏筛选工具，识别它们对疾病进展的个体贡献以及识别PCa中可治疗性miRNA靶点一直具有挑战性。为了满足这一需求，我们开发了miRKOv2，这是一个仅包含miRNA的CRISPR敲除文库，能够进行系统性、全基因组功能缺失筛选，以识别对PCa细胞存活至关重要的miRNA。我们的筛选发现了70个潜在的关键miRNA候选物，其中miR-483对PCa细胞活力的影响最为显著。功能表征显示，miR-483的破坏增强了PCa细胞系的凋亡。从机制上讲，我们发现了一个新的调控轴，其中miR-483-3p直接调节BCLAF1/PUMA/BAK1凋亡信号网络，突显了其在维持PCa细胞存活中的关键作用。我们的发现为miRNA在PCa进展中的复杂调控作用提供了新的见解，并为靶向转移性疾病中miRNA介导的通路提供了一种潜在的治疗策略。

### 第二部分 AI 大师评价

本研究通过开发miRKOv2这一创新的miRNA特异性CRISPR敲除文库，系统性地筛选了前列腺癌细胞存活所必需的miRNA。研究发现miR-483-3p在前列腺癌细胞凋亡调控中发挥关键作用，并首次揭示了其通过直接调控BCLAF1/PUMA/BAK1凋亡信号网络维持癌细胞存活的分子机制。该研究的创新性在于建立了专门针对miRNA的功能性筛选平台，克服了传统miRNA研究工具的局限性，为开发基于miRNA的靶向治疗提供了重要理论基础。虽然研究主要集中在细胞水平验证，但为转移性前列腺癌的治疗策略开发开辟了新的方向，具有重要的临床转化价值。

---

## 22. PFKFB3作为去势抵抗性前列腺癌的多方面驱动因子和治疗靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136393](https://pubmed.ncbi.nlm.nih.gov/41136393)
**期刊：** Cell death & disease
**PMID：** 41136393
**DOI：** 10.1038/s41419-025-08089-8

### 第一部分 原文与翻译

**英文原标题：** PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer.

**英文摘要原文：**
Castration-resistant prostate cancer (CRPC) is the advanced stage of prostate cancer (PCa) progression, characterized by limited therapeutic options and significant challenges from drug resistance development. We show that PFKFB3, an essential regulator of glycolytic metabolism, is significantly upregulated in PCa tissues and CRPC cell lines, where it plays a pivotal role in driving CRPC progression. Knockdown of PFKFB3 or inhibition by a small molecule inhibitor significantly inhibits the growth and invasion of CRPC cells, whereas overexpression promotes malignant behaviors. Mechanistically, PFKFB3 modulates the PI3K/Akt-Wnt/β-catenin pathway, resulting in enhanced tumor cell proliferation. Additionally, combining a PFKFB3 inhibitor with docetaxel produces synergistic anti-CRPC effects and reduces toxicity. Therefore, PFKFB3-mediated metabolic reprogramming underlies CRPC progression, highlighting its potential as a therapeutic target and emphasizing the need for further exploration in the development of safe and effective PFKFB3 inhibitors for precise targeted therapy in CRPC.

**中文摘要译文：**
去势抵抗性前列腺癌（CRPC）是前列腺癌进展的晚期阶段，其特征是治疗选择有限且面临药物耐药性发展的重大挑战。我们发现PFKFB3（糖酵解代谢的关键调节因子）在前列腺癌组织和CRPC细胞系中显著上调，并在驱动CRPC进展中发挥关键作用。敲低PFKFB3或通过小分子抑制剂抑制其活性显著抑制CRPC细胞的生长和侵袭，而过表达则促进恶性行为。从机制上讲，PFKFB3调节PI3K/Akt-Wnt/β-catenin通路，导致肿瘤细胞增殖增强。此外，将PFKFB3抑制剂与多西他赛联合使用可产生协同抗CRPC效应并降低毒性。因此，PFKFB3介导的代谢重编程是CRPC进展的基础，突显了其作为治疗靶点的潜力，并强调需要进一步探索开发安全有效的PFKFB3抑制剂，以实现CRPC的精准靶向治疗。

### 第二部分 AI 大师评价

本研究系统揭示了PFKFB3在去势抵抗性前列腺癌中的关键作用机制。研究团队通过基因敲低、抑制剂干预和过表达实验，证实PFKFB3通过调节PI3K/Akt-Wnt/β-catenin信号通路促进肿瘤恶性进展。该研究的创新性在于将代谢重编程与CRPC治疗联系起来，特别是发现PFKFB3抑制剂与多西他赛联合治疗的协同效应，为克服CRPC耐药性提供了新策略。虽然研究为临床转化提供了重要理论基础，但未来仍需进一步验证PFKFB3抑制剂的安全性和体内疗效，这有望为晚期前列腺癌患者带来新的精准治疗选择。

---

## 23. SETDB1对葡萄膜黑色素瘤生长至关重要，是一个有前景的治疗靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136387](https://pubmed.ncbi.nlm.nih.gov/41136387)
**期刊：** Cell death & disease
**PMID：** 41136387
**DOI：** 10.1038/s41419-025-08084-z

### 第一部分 原文与翻译

**英文原标题：** SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.

**英文摘要原文：**
Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, we conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin regulators. We revealed that the lysine methyltransferase, SETDB1, plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 deficiency induces a DNA damage response, senescence-like state and growth arrest. Knockdown of SETDB1 is associated with a decreased expression of genes related to replication and cell cycle. Moreover, deficiency in CDC6, an essential regulator of DNA replication, phenocopies SETDB1 inhibition. Using a pre-clinical model, we further demonstrated that anti-SETDB1 therapy impairs tumor growth in vivo. Therefore, we not only provide evidence that SETDB1 plays a critical role in metastatic uveal melanoma cell growth, but we also identify SETDB1 as a novel relevant therapeutic target for the treatment of metastatic uveal melanoma.

**中文摘要译文：**
转移性葡萄膜黑色素瘤对所有现有治疗方法均表现出高度耐药性。为了识别可行的治疗靶点，我们使用由染色质调节因子组成的文库进行了CRISPR-Cas9敲除筛选。我们发现赖氨酸甲基转移酶SETDB1在转移性葡萄膜黑色素瘤细胞增殖和存活中发挥关键作用。从功能上看，SETDB1缺失会诱导DNA损伤反应、衰老样状态和生长停滞。SETDB1敲低与复制和细胞周期相关基因表达降低相关。此外，DNA复制关键调节因子CDC6的缺失模拟了SETDB1抑制的表型。使用临床前模型，我们进一步证明抗SETDB1治疗在体内损害肿瘤生长。因此，我们不仅提供了SETDB1在转移性葡萄膜黑色素瘤细胞生长中发挥关键作用的证据，而且还将SETDB1确定为治疗转移性葡萄膜黑色素瘤的一个新的相关治疗靶点。

### 第二部分 AI 大师评价

本研究通过CRISPR-Cas9筛选技术系统性地探索了转移性葡萄膜黑色素瘤的治疗靶点，具有重要的创新性。研究团队发现SETDB1这一表观遗传调节因子在肿瘤细胞增殖和存活中的关键作用，揭示了其通过调控DNA复制和细胞周期相关基因表达来维持肿瘤生长的机制。该研究不仅提供了新的生物学机制认识，更重要的是通过临床前模型验证了靶向SETDB1的治疗潜力，为目前缺乏有效治疗手段的转移性葡萄膜黑色素瘤提供了有前景的治疗策略。然而，研究尚未深入探讨SETDB1抑制剂的具体开发路径和潜在的毒副作用，这些将是未来转化研究的重要方向。

---

## 24. HOTAIR需要表观转录组修饰才能在上皮-间质转化中发挥其关键的表观遗传作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136384](https://pubmed.ncbi.nlm.nih.gov/41136384)
**期刊：** Cell death & disease
**PMID：** 41136384
**DOI：** 10.1038/s41419-025-08099-6

### 第一部分 原文与翻译

**英文原标题：** HOTAIR requires epitranscriptomic modification to exert its pivotal epigenetic role in Epithelial to Mesenchymal Transition.

**英文摘要原文：**
While m6A epitranscriptomic modification has been shown to impact several mRNAs maturation, stability/degradation, nuclear/cytoplasm export and translation regulation, its impact on lncRNAs activity is yet largely uncharacterized. Here, we show that the silencing of the m6A writer METTL3 inhibits Epithelial to Mesenchymal Transition (EMT), morphological, migratory and invasive features of TGFβ-treated epithelial cells as well as of tumor cells. Building on previous evidence pinpointing the lncHOTAIR as a mandatory element for epithelial genes' repression triggering EMT, here we uncover a dominant role of an epitranscriptomic modification on the epigenetic function of this lncRNA. Mechanistically, HOTAIR is m6A-modified on the interaction domains with both the master transcriptional factor of EMT SNAIL and the general chromatin modifier EZH2. This epitranscriptomic modification is necessary for the interaction between HOTAIR and SNAIL/EZH2 and in turn for HOTAIR-dependent epigenetic repression on SNAIL-targeted epithelial genes. Impairing m6A modification impedes the assembling of the tripartite SNAIL/HOTAIR/EZH2 complex and in turn blocks EMT accomplishment. Overall, we unveil that the epitranscriptomic modification m6A has a dominant role on the epigenetic function of a lncRNA.

**中文摘要译文：**
虽然m6A表观转录组修饰已被证明影响多种mRNA的成熟、稳定性/降解、核/质输出和翻译调控，但其对lncRNA活性的影响在很大程度上仍未得到充分表征。在此，我们发现沉默m6A写入酶METTL3可抑制TGFβ处理的上皮细胞以及肿瘤细胞的上皮-间质转化（EMT）、形态学、迁移和侵袭特征。基于先前证据表明lncHOTAIR是触发EMT的上皮基因抑制的必要元素，我们在此揭示了表观转录组修饰对该lncRNA表观遗传功能的主导作用。从机制上讲，HOTAIR在与EMT主转录因子SNAIL和通用染色质修饰剂EZH2的相互作用域上被m6A修饰。这种表观转录组修饰对于HOTAIR与SNAIL/EZH2之间的相互作用是必需的，进而对于HOTAIR依赖的对SNAIL靶向上皮基因的表观遗传抑制也是必需的。损害m6A修饰会阻碍三方SNAIL/HOTAIR/EZH2复合物的组装，进而阻断EMT的完成。总体而言，我们揭示了表观转录组修饰m6A在lncRNA的表观遗传功能中具有主导作用。

### 第二部分 AI 大师评价

本研究通过分子机制探索，揭示了m6A表观转录组修饰在调控lncRNA HOTAIR表观遗传功能中的关键作用。研究采用METTL3沉默实验，结合分子相互作用分析，发现HOTAIR的m6A修饰是其与SNAIL/EZH2形成功能性复合物的必要条件，从而调控上皮-间质转化过程。这一发现具有重要的创新性，首次建立了表观转录组修饰与lncRNA表观遗传功能之间的直接联系，为理解肿瘤转移机制提供了新视角。研究局限性在于主要基于体外细胞模型，未来需要体内实验验证其生理相关性，但该机制可能为开发靶向EMT的癌症治疗策略提供新的分子靶点。

---

## 25. 胰岛素降解酶通过抑制Hippo信号通路在帕金森病中发挥神经保护作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136383](https://pubmed.ncbi.nlm.nih.gov/41136383)
**期刊：** Cell death & disease
**PMID：** 41136383
**DOI：** 10.1038/s41419-025-08055-4

### 第一部分 原文与翻译

**英文原标题：** Insulin-degrading enzyme confers neuroprotection in Parkinson's disease by inhibiting the Hippo signaling pathway.

**英文摘要原文：**
Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily marked by the degeneration of dopaminergic neurons and pathological α-synuclein (α-syn) accumulation. Although insulin-degrading enzyme (IDE) has been implicated in both type 2 diabetes mellitus and amyloid-protein clearance, its precise relevance to PD pathogenesis remains unclear. In this study, we show that IDE expression is reduced in the nigrostriatal region of aging homozygous A53T α-syn mice and in α-syn-overexpressing SH-SY5Y PD cells. Overexpression of IDE alleviated motor deficits, reduced pathological α-syn levels, and protected dopaminergic neurons in A53T α-syn mice. In SH-SY5Y PD model cells, IDE overexpression reduced α-syn-induced toxicity, whereas IDE knockdown exacerbated it. Integrated transcriptomic and proteomic analyses revealed that the Hippo signaling pathway serves as a major downstream target of IDE. Notably, inhibition of MST1/2, a pivotal Hippo kinase, recapitulated IDE's neuroprotective effects by diminishing α-syn pathology and neuronal apoptosis. Hence, IDE confers neuroprotection partly via suppression of the Hippo signaling pathway, and pharmacological targeting of the IDE-Hippo axis may represent a promising therapeutic strategy for PD.

**中文摘要译文：**
帕金森病（PD）是一种进行性神经退行性疾病，主要特征是多巴胺能神经元的退化和病理性α-突触核蛋白（α-syn）的积累。尽管胰岛素降解酶（IDE）在2型糖尿病和淀粉样蛋白清除中均有涉及，但其与PD发病机制的确切相关性仍不清楚。在本研究中，我们发现IDE表达在衰老的纯合A53T α-syn小鼠的黑质纹状体区域和过表达α-syn的SH-SY5Y PD细胞中均降低。IDE的过表达减轻了A53T α-syn小鼠的运动缺陷，降低了病理性α-syn水平，并保护了多巴胺能神经元。在SH-SY5Y PD模型细胞中，IDE过表达减少了α-syn诱导的毒性，而IDE敲低则加剧了这种毒性。整合转录组学和蛋白质组学分析显示，Hippo信号通路是IDE的主要下游靶点。值得注意的是，抑制关键的Hippo激酶MST1/2通过减少α-syn病理和神经元凋亡，重现了IDE的神经保护作用。因此，IDE通过抑制Hippo信号通路部分发挥神经保护作用，而药理学靶向IDE-Hippo轴可能代表了一种有前景的PD治疗策略。

### 第二部分 AI 大师评价

本研究系统阐明了胰岛素降解酶（IDE）在帕金森病中的神经保护机制，揭示了其通过抑制Hippo信号通路发挥保护作用的新机制。研究采用转基因小鼠模型和细胞模型，结合多组学分析，证实IDE表达下调与PD病理相关，而IDE过表达可改善运动功能、减少α-突触核蛋白病理并保护多巴胺能神经元。该研究的创新性在于首次将IDE-Hippo信号轴与PD发病机制联系起来，为理解PD的分子机制提供了新视角。这一发现具有重要的临床转化价值，为开发靶向IDE-Hippo轴的新型PD治疗策略奠定了理论基础，但需进一步验证其在人类PD患者中的适用性。

---

## 26. UHRF1介导的HIF-1α稳定化通过代谢重编程和血管生成促进卵巢癌发展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136379](https://pubmed.ncbi.nlm.nih.gov/41136379)
**期刊：** Cell death & disease
**PMID：** 41136379
**DOI：** 10.1038/s41419-025-08033-w

### 第一部分 原文与翻译

**英文原标题：** UHRF1-mediated HIF-1α stabilization promotes ovarian cancer through metabolic reprogramming and angiogenesis.

**英文摘要原文：**
Ubiquitin-like PHD and RING finger domain-containing protein 1 (UHRF1) is an important epigenetic regulatory factor that is highly expressed in various cancers and participates in tumorigenesis and progression. However, the role and molecular mechanisms of UHRF1 in ovarian cancer (OC) remain unclear. Through survival analysis, cellular functional experiments, and animal studies, we identified UHRF1 as a key gene influencing OC progression and prognosis. Hypoxia-inducible factor-1 (HIF-1α), a well-known pro-cancer molecule, undergoes classic degradation via the ubiquitin-proteasome pathway. We discovered that UHRF1 interacts with HIF-1α, affecting its hydroxylation level, thereby inhibiting HIF-1α polyubiquitination and degradation. Functional experiments revealed that knocking down HIF-1α in stable UHRF1-overexpressing cell lines significantly reversed the malignant phenotype of OC cells. Furthermore, UHRF1 can also regulate the expression of key downstream molecules such as GLUT1, HK2, LDHA, and VEGFA by modulating HIF-1α, thus influencing tumor cell metabolism and angiogenesis. In summary, our findings suggest that UHRF1 plays a crucial role in the development of OC by regulating the expression of HIF-1α.

**中文摘要译文：**
类泛素PHD和RING指结构域蛋白1（UHRF1）是一种重要的表观遗传调控因子，在多种癌症中高表达并参与肿瘤发生和进展。然而，UHRF1在卵巢癌（OC）中的作用和分子机制仍不清楚。通过生存分析、细胞功能实验和动物研究，我们确定UHRF1是影响OC进展和预后的关键基因。缺氧诱导因子-1α（HIF-1α）是一种众所周知的促癌分子，通过泛素-蛋白酶体途径进行经典降解。我们发现UHRF1与HIF-1α相互作用，影响其羟基化水平，从而抑制HIF-1α的多泛素化和降解。功能实验显示，在稳定过表达UHRF1的细胞系中敲低HIF-1α显著逆转了OC细胞的恶性表型。此外，UHRF1还可以通过调控HIF-1α来调节关键下游分子如GLUT1、HK2、LDHA和VEGFA的表达，从而影响肿瘤细胞代谢和血管生成。总之，我们的研究结果表明UHRF1通过调控HIF-1α的表达在OC发展中起着至关重要的作用。

### 第二部分 AI 大师评价

本研究系统阐明了UHRF1在卵巢癌中的新机制，通过揭示其与HIF-1α的相互作用以及抑制HIF-1α降解的分子通路，填补了该领域的重要空白。研究采用生存分析、细胞功能实验和动物模型相结合的多层次验证策略，方法学严谨可靠。关键发现表明UHRF1通过稳定HIF-1α调控代谢重编程（GLUT1、HK2、LDHA）和血管生成（VEGFA），为卵巢癌治疗提供了新的潜在靶点。该研究的创新性在于首次建立了UHRF1-HIF-1α轴在卵巢癌中的作用机制，具有重要的临床转化价值，但需进一步验证其在其他肿瘤类型中的普适性。

---

## 27. SH2B3基因突变在疑似髓系恶性肿瘤和急性白血病中的诊断相关性：基于大规模NGS筛查研究的深入分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136376](https://pubmed.ncbi.nlm.nih.gov/41136376)
**期刊：** Blood cancer journal
**PMID：** 41136376
**DOI：** 10.1038/s41408-025-01392-9

### 第一部分 原文与翻译

**英文原标题：** Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies and acute leukemia: insights from a large-scale NGS-based screening study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究通过大规模NGS筛查方法，深入探讨了SH2B3基因突变在疑似髓系恶性肿瘤和急性白血病中的诊断价值。该研究采用高通量测序技术对大量样本进行系统性分析，旨在明确SH2B3突变在血液系统恶性肿瘤诊断中的临床意义。研究创新性地聚焦于SH2B3这一相对较少研究的基因，为血液肿瘤的分子诊断提供了新的生物标志物，具有重要的临床应用前景。然而，由于摘要信息有限，无法详细了解具体的研究设计、样本规模以及关键发现，建议进一步查阅全文以获得更全面的研究信息。

---

## 28. 非泛素化途径调控脊索瘤进展中的RIT1-MAPK通路

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136369](https://pubmed.ncbi.nlm.nih.gov/41136369)
**期刊：** Cell death & disease
**PMID：** 41136369
**DOI：** 10.1038/s41419-025-08092-z

### 第一部分 原文与翻译

**英文原标题：** Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.

**英文摘要原文：**
Chordoma is a rare, slow-growing malignant tumor originating from embryonic notochord remnants and is often found in the sacrum or skull base. It is categorized into conventional, poorly differentiated, and dedifferentiated types, with the conventional type being the most common. Owing to its location near critical structures, chordoma has a high rate of local recurrence, making new therapeutic targets essential. The proteasome system, which is responsible for degrading intracellular proteins, plays a vital role in maintaining cellular function. REGγ, a proteasome activator, mediates ubiquitin-, and ATP-independent protein degradation and is overexpressed in various cancers. However, its role in chordoma remains unexplored. Ras GTPases, including RIT1, are involved in cancer progression, and understanding their involvement in chordoma could provide therapeutic insights. This study identified REGγ as a potential therapeutic target for chordoma. REGγ was found to be upregulated in chordoma, and high REGγ expression was correlated with poor clinical outcomes. It promotes cell proliferation and migration, and inhibits apoptosis, while influencing osteoclast differentiation. Mechanistically, REGγ regulates chordoma progression through the ubiquitin- and ATP-independent degradation of RIT1, which modulates the RIT1-MAPK pathway. Inhibition of RIT1 in REGγ-knockdown cells and patient-derived organoids alleviated these effects, suggesting that targeting REGγ may be a promising strategy for chordoma treatment.

**中文摘要译文：**
脊索瘤是一种罕见的、生长缓慢的恶性肿瘤，起源于胚胎脊索残余，常见于骶骨或颅底。它分为经典型、低分化型和去分化型，其中经典型最为常见。由于位于关键结构附近，脊索瘤具有较高的局部复发率，因此寻找新的治疗靶点至关重要。蛋白酶体系统负责降解细胞内蛋白质，在维持细胞功能中起着至关重要的作用。REGγ是一种蛋白酶体激活剂，介导不依赖泛素和ATP的蛋白质降解，并在多种癌症中过度表达。然而，其在脊索瘤中的作用尚未被探索。Ras GTPases（包括RIT1）参与癌症进展，了解它们在脊索瘤中的参与可能提供治疗见解。本研究确定REGγ是脊索瘤的潜在治疗靶点。发现REGγ在脊索瘤中上调，高REGγ表达与不良临床结局相关。它促进细胞增殖和迁移，抑制细胞凋亡，同时影响破骨细胞分化。机制上，REGγ通过不依赖泛素和ATP的RIT1降解来调控脊索瘤进展，从而调节RIT1-MAPK通路。在REGγ敲低细胞和患者来源的类器官中抑制RIT1可减轻这些效应，表明靶向REGγ可能是脊索瘤治疗的有前景策略。

### 第二部分 AI 大师评价

本研究首次揭示了REGγ在脊索瘤中的关键作用机制，创新性地发现了其通过非泛素化途径降解RIT1蛋白来调控MAPK信号通路。研究采用多层次的实验方法，包括临床样本分析、细胞功能实验和患者来源的类器官模型，系统验证了REGγ-RIT1-MAPK轴在脊索瘤进展中的核心地位。该发现不仅为理解脊索瘤的分子机制提供了新视角，更重要的是为这种难治性肿瘤提供了潜在的治疗靶点。虽然研究在机制探索方面较为深入，但未来仍需在动物模型和临床前研究中进一步验证靶向REGγ的治疗效果。

---

## 29. 聚焦高剂量治疗与自体干细胞移植的35年学术试验历程：法国骨髓瘤协作组(IFM)经验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136366](https://pubmed.ncbi.nlm.nih.gov/41136366)
**期刊：** Blood cancer journal
**PMID：** 41136366
**DOI：** 10.1038/s41408-025-01387-6

### 第一部分 原文与翻译

**英文原标题：** 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

**英文摘要原文：**
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.

**中文摘要译文：**
截至2025年，高剂量治疗(HDT)已成为适合自体干细胞移植(ASCT)的多发性骨髓瘤(MM)患者的一线标准治疗方案。在高剂量马法兰治疗前，如条件允许，也系统性推荐采用四联组合方案进行诱导治疗。根据国际指南，还建议使用来那度胺维持治疗直至疾病进展。这一治疗策略是基于不同学术团体设计和实施的3期临床试验结果，在过去几十年中逐步发展完善的。随着这些治疗进展，多发性骨髓瘤患者的中位总生存期(OS)已从1990年代的5年延长至目前的15年以上。本文介绍了法国骨髓瘤协作组(IFM)在新诊断适合移植(NDTE)患者治疗进展中所做出的贡献。

### 第二部分 AI 大师评价

本研究系统回顾了法国骨髓瘤协作组(IFM)35年来在高剂量治疗与自体干细胞移植领域的学术试验经验。研究采用回顾性分析方法，总结了IFM在适合移植的多发性骨髓瘤患者治疗策略发展中的关键贡献。核心发现表明，通过优化诱导治疗、高剂量化疗和维持治疗策略，患者中位总生存期从5年显著延长至15年以上。该研究具有重要的临床价值，为多发性骨髓瘤治疗提供了循证医学依据，但其回顾性设计可能存在选择偏倚，且主要反映特定地区经验，需更多前瞻性研究验证其普适性。

---

## 30. 从缓解到治愈：Tali-cel™ CD19 CAR-T疗法在复发/难治性儿童B细胞急性淋巴细胞白血病试验中未解决的临床挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136365](https://pubmed.ncbi.nlm.nih.gov/41136365)
**期刊：** Blood cancer journal
**PMID：** 41136365
**DOI：** 10.1038/s41408-025-01388-5

### 第一部分 原文与翻译

**英文原标题：** From response to cure: Unaddressed clinical challenges in the Tali-cel™ CD19 CAR-T trial for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于Tali-cel™ CD19 CAR-T疗法在复发/难治性儿童B细胞急性淋巴细胞白血病临床试验中面临的临床挑战。研究旨在探讨从治疗反应到实现真正治愈过程中存在的关键障碍，分析CAR-T疗法在儿科血液肿瘤领域的应用局限。该研究具有重要的临床价值，有助于识别CAR-T疗法在儿童患者中的特殊挑战，为优化治疗策略提供依据。然而，由于缺乏摘要信息，无法详细了解具体的研究方法、关键发现和创新性，这在一定程度上限制了对其学术价值的全面评估。

---

## 31. 急性髓系白血病特异性T细胞应答及靶向共享新抗原的T细胞受体鉴定

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136363](https://pubmed.ncbi.nlm.nih.gov/41136363)
**期刊：** Blood cancer journal
**PMID：** 41136363
**DOI：** 10.1038/s41408-025-01370-1

### 第一部分 原文与翻译

**英文原标题：** Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia.

**英文摘要原文：**
Accumulation of genetic mutations in malignant myeloid precursor cells leads to an extremely poor prognosis for patients with acute myeloid leukemia (AML). Immunogenic neoantigens recognized by T cell receptor (TCR) can elicit effective immune responses against malignant cells with corresponding somatic mutations. To broaden the range of targeted treatments for AML, in this study, we explored the feasibility of immunotherapy targeting neoantigens arising from recurrent mutations, which are exclusively present on leukemic cells. We used data-driven methods to select seven neoantigens from four frequently mutated genes (NPM1, FLT3, TP53, and DNMT3A) associated with HLA-A02:01-positive AML patients. Functional assays demonstrated that neoantigens derived from NPM1/W288fs, FLT3/D835H, and FLT3/D835Y were shown to induce specific T cell responses in AML patients. We further identified the specific TCR sequences from healthy donors capable of recognizing these neoantigens. In-depth studies of their specific T cells revealed the presence of dominant αβTCRs that could specifically recognize NPM1/W288fs and FLT3/D835H in an HLA-A02:01-restricted manner. T cells engineered with each αβTCR selectively recognized and killed HLA-A02:01-positive AML targets endogenously expressing corresponding mutations. Overall, our findings support the clinical translation of adoptive neoantigen-specific TCR-engineered T cells as a novel therapeutic strategy for treating AML.

**中文摘要译文：**
恶性髓系前体细胞中遗传突变的积累导致急性髓系白血病（AML）患者预后极差。被T细胞受体（TCR）识别的免疫原性新抗原能够引发针对具有相应体细胞突变的恶性细胞的有效免疫应答。为了扩大AML靶向治疗的范围，本研究探讨了靶向由复发突变产生的新抗原（这些新抗原仅在白血病细胞上存在）的免疫治疗的可行性。我们采用数据驱动的方法，从与HLA-A02:01阳性AML患者相关的四个频繁突变基因（NPM1、FLT3、TP53和DNMT3A）中筛选出七个新抗原。功能测定表明，源自NPM1/W288fs、FLT3/D835H和FLT3/D835Y的新抗原能够诱导AML患者产生特异性T细胞应答。我们进一步从健康供者中鉴定出能够识别这些新抗原的特异性TCR序列。对其特异性T细胞的深入研究揭示了存在优势αβTCRs，这些受体能够以HLA-A02:01限制性方式特异性识别NPM1/W288fs和FLT3/D835H。用每种αβTCR工程改造的T细胞选择性地识别并杀死了内源性表达相应突变的HLA-A02:01阳性AML靶细胞。总的来说，我们的研究结果支持将过继性新抗原特异性TCR工程化T细胞作为治疗AML的新型治疗策略进行临床转化。

### 第二部分 AI 大师评价

本研究旨在探索针对急性髓系白血病（AML）复发突变产生的新抗原的免疫治疗可行性，核心目的是开发新型靶向治疗策略。研究团队采用数据驱动方法筛选新抗原，并通过功能性实验验证了NPM1/W288fs、FLT3/D835H和FLT3/D835Y等新抗原诱导特异性T细胞应答的能力。关键发现包括鉴定出能够特异性识别这些新抗原的αβTCRs，并证实工程化T细胞能够选择性杀伤表达相应突变的AML细胞。该研究的创新性在于针对AML共享新抗原开发TCR工程化T细胞疗法，为这一难治性血液肿瘤提供了精准免疫治疗新思路。然而，研究主要局限于HLA-A02:01阳性患者群体，未来需要扩展到其他HLA类型以扩大适用人群。

---

## 32. TM9SF1通过AMPK-ULK1信号通路驱动脂噬流以维持HER2阳性乳腺癌的代谢适应性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136362](https://pubmed.ncbi.nlm.nih.gov/41136362)
**期刊：** Cell death & disease
**PMID：** 41136362
**DOI：** 10.1038/s41419-025-08093-y

### 第一部分 原文与翻译

**英文原标题：** TM9SF1 drives the lipophagic flux via AMPK-ULK1 signaling to sustain metabolic fitness in HER2-positive breast cancer.

**英文摘要原文：**
Therapeutic resistance and recurrence in human epidermal growth factor receptor 2-positive breast cancer (HER2 + BC) remain critical challenges that portend poor patient outcomes. Dysregulated autophagy and lipid metabolism contribute to tumor progression, yet the crosstalk between these pathways is poorly understood. This study investigates the role of transmembrane 9 superfamily member 1 (TM9SF1) in lipophagy and lipid metabolic reprogramming in HER2 + BC under metabolic stress. Clinically, TM9SF1 was significantly upregulated in HER2 + BC tissues and correlated with poor prognosis. Functionally, its expression correlated with markers of enhanced autophagy and lysosomal lipid catabolism, and it promoted tumor cell proliferation in vitro and in vivo. Conversely, TM9SF1 knockdown suppressed lipophagy under both basal and starvation conditions, inhibiting lipid droplet (LD) hydrolysis and the conversion of triglycerides to free fatty acids. This suppression was phenotypically characterized by LD accumulation, reduced autophagosomes and lipophagosomes, and altered enzymatic and lipidomic profiles. Mechanistically, TM9SF1 sustained lipophagy by promoting the phosphorylation of AMP-activated protein kinase at Thr172 and UNC-51-like kinase 1 at Ser555. Consequently, TM9SF1 was pivotal for lipid metabolic reprogramming, maintaining energy homeostasis and enhancing adaptation to nutrient deprivation through lipophagy. Overall, our findings identify TM9SF1 as a key HER2 + BC-associated regulator that drives lipophagy via the AMP-activated protein kinase-UNC-51-like kinase 1 pathway, facilitating LD turnover and free fatty acids utilization to sustain energy homeostasis in HER2 + BC. This work establishes a critical link between malignant phenotypes and metabolic resilience. Targeting this regulatory network represents a promising strategy to dismantle the metabolic scaffolds underlying HER2 + BC aggressiveness and therapeutic resistance.

**中文摘要译文：**
人表皮生长因子受体2阳性乳腺癌（HER2+BC）的治疗耐药性和复发仍然是预示患者预后不良的关键挑战。失调的自噬和脂质代谢促进肿瘤进展，但这些通路之间的相互作用尚不清楚。本研究探讨了跨膜9超家族成员1（TM9SF1）在代谢应激下HER2+BC中脂噬和脂质代谢重编程中的作用。临床上，TM9SF1在HER2+BC组织中显著上调，并与不良预后相关。功能上，其表达与增强的自噬和溶酶体脂质分解代谢标志物相关，并在体外和体内促进肿瘤细胞增殖。相反，TM9SF1敲低在基础和饥饿条件下均抑制了脂噬，抑制了脂滴（LD）水解和甘油三酯向游离脂肪酸的转化。这种抑制在表型上表现为LD积累、自噬体和脂噬体减少以及酶和脂质组谱的改变。机制上，TM9SF1通过促进AMP活化蛋白激酶在Thr172位点和UNC-51样激酶1在Ser555位点的磷酸化来维持脂噬。因此，TM9SF1对于脂质代谢重编程、维持能量稳态和通过脂噬增强对营养剥夺的适应至关重要。总的来说，我们的研究结果确定TM9SF1是一个关键的HER2+BC相关调节因子，通过AMP活化蛋白激酶-UNC-51样激酶1通路驱动脂噬，促进LD周转和游离脂肪酸利用，以维持HER2+BC中的能量稳态。这项工作建立了恶性表型和代谢韧性之间的关键联系。靶向这一调控网络代表了一种有前景的策略，可以瓦解HER2+BC侵袭性和治疗耐药性基础的代谢支架。

### 第二部分 AI 大师评价

本研究深入探讨了TM9SF1在HER2阳性乳腺癌脂质代谢重编程中的关键作用。研究采用临床样本分析、体外功能实验和机制探索相结合的方法，系统揭示了TM9SF1通过AMPK-ULK1信号通路调控脂噬的新机制。创新性地发现了TM9SF1作为连接自噬与脂质代谢的重要桥梁，为理解肿瘤代谢适应性提供了新视角。该研究具有重要的临床价值，不仅解释了HER2阳性乳腺癌治疗耐药的代谢基础，还为开发针对代谢通路的联合治疗策略提供了潜在靶点。然而，研究在临床应用转化方面仍需进一步验证，且对TM9SF1在其他肿瘤类型中的普适性有待探索。

---

## 33. 细胞稳定性的双重守护者：探索衰老过程中的Nesprin和Lamin蛋白

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136356](https://pubmed.ncbi.nlm.nih.gov/41136356)
**期刊：** Cell death & disease
**PMID：** 41136356
**DOI：** 10.1038/s41419-025-08087-w

### 第一部分 原文与翻译

**英文原标题：** The dual guardians of cellular stability: exploring nesprin and lamin in senescence.

**英文摘要原文：**
Cellular senescence is a state where cells permanently exit the cell cycle after a finite number of divisions, while maintaining metabolic activity. This phenomenon, initially described by Leonard Hayflick, plays a pivotal role in aging, contributing to the progressive decline in physiological function by promoting tissue dysfunction and restricting regenerative capacity. It is regulated by an array of factors, including DNA damage, telomere shortening, oxidative stress, mitochondrial dysfunction, and epigenetic modifications. Nesprins, a family of transmembrane proteins embedded in the nuclear envelope, are integral components of the LINC (Linker of Nucleoskeleton and Cytoskeleton) complex, which connects the nucleus to the cytoskeleton, thus preserving structural integrity and facilitating mechanotransduction. Lamin proteins, which form the nuclear lamina beneath the inner nuclear membrane, provide support to nuclear envelope architecture, organize chromatin, and modulate gene expression. Lamin proteins also interact with nesprins to collectively sustain nuclear mechanics and maintain morphological stability. Understanding the molecular mechanisms by which nesprins and lamins influence cellular senescence provides valuable insights into the biology of aging and may offer novel therapeutic avenues to address age-related diseases. This review examines the interactions between nesprin and lamin proteins and their potential contributions to cellular senescence.

**中文摘要译文：**
细胞衰老是一种细胞在经历有限次数的分裂后永久退出细胞周期，同时保持代谢活性的状态。这一现象最初由Leonard Hayflick描述，在衰老过程中发挥着关键作用，通过促进组织功能障碍和限制再生能力，导致生理功能的渐进性衰退。它受到一系列因素的调控，包括DNA损伤、端粒缩短、氧化应激、线粒体功能障碍和表观遗传修饰。Nesprins是一类嵌入核膜的跨膜蛋白家族，是LINC（核骨架与细胞骨架连接体）复合物的组成部分，该复合物连接细胞核与细胞骨架，从而维持结构完整性并促进机械转导。Lamin蛋白在内核膜下方形成核纤层，为核膜结构提供支持，组织染色质，并调节基因表达。Lamin蛋白还与nesprins相互作用，共同维持核力学和形态稳定性。理解nesprins和lamins影响细胞衰老的分子机制，为衰老生物学提供了宝贵的见解，并可能为解决与年龄相关疾病提供新的治疗途径。本综述探讨了nesprin和lamin蛋白之间的相互作用及其对细胞衰老的潜在贡献。

### 第二部分 AI 大师评价

本研究通过综述性分析，深入探讨了nesprin和lamin蛋白在细胞衰老过程中的协同作用机制。研究采用文献综述方法，系统阐述了这两种蛋白作为细胞核-细胞骨架连接的关键分子，如何通过维持核力学稳定性和形态完整性来影响衰老进程。该研究的创新性在于提出了"细胞稳定性的双重守护者"这一概念，强调了核膜蛋白在衰老生物学中的核心地位。这一发现具有重要的科研价值，不仅深化了对衰老分子机制的理解，还为开发针对年龄相关疾病的干预策略提供了新的理论依据。然而，作为综述性研究，其局限性在于缺乏直接的实验验证，未来需要更多的功能研究来证实这些分子机制。

---

## 34. 低白蛋白血症：意义未明单克隆丙种球蛋白病患者进展的新风险因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41136351](https://pubmed.ncbi.nlm.nih.gov/41136351)
**期刊：** Blood cancer journal
**PMID：** 41136351
**DOI：** 10.1038/s41408-025-01371-0

### 第一部分 原文与翻译

**英文原标题：** Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance.

**英文摘要原文：**
Recent studies have advanced the understanding of the pathogenesis of monoclonal gammopathy of uncertain significance (MGUS), describing the influence of a proinflammatory bone marrow environment on the risk of progression. While albumin is a known inflammatory prognostic biomarker in multiple myeloma, its role in MGUS has not been explored. We conducted a retrospective study to investigate the prognostic value of albumin in MGUS. Eight hundred and thirty-eight patients with MGUS were included: 71 (8.5%) presented hypoalbuminemia (≤3.5 g/dL) at diagnosis. Hypoalbuminemia was more common in men (63.4% vs. 49.3%; P = 0.025), older age (≥70 years: 74.6% vs. 57.2%; P = 0.005), and IgA isotype (33.8% vs. 21.4%; P = 0.018). These patients presented lower hemoglobin levels and higher creatinine values (P < 0.001 and P < 0.001). Serum M protein ≥ 1.5 g/dL (HR 18.9 [95% CI, 1.8-200.8]; P = 0.015) and hypoalbuminemia (HR 14.7 [95% CI, 1.7-124.7]; P = 0.014) were identified as independent prognostic factors for progression. In our series, Mayo Clinic and MGUS-like phenotype models were validated, and the incorporation of hypoalbuminemia into these models helped identify a subgroup of intermediate-risk patients with a higher risk of progression. In conclusion, if confirmed by independent studies, hypoalbuminemia could be integrated into existing prognostic models, improving risk stratification and guiding clinical decision-making.

**中文摘要译文：**
近期研究加深了对意义未明单克隆丙种球蛋白病（MGUS）发病机制的理解，描述了促炎性骨髓环境对进展风险的影响。虽然白蛋白是多发性骨髓瘤中已知的炎症预后生物标志物，但其在MGUS中的作用尚未被探索。我们进行了一项回顾性研究，以探讨白蛋白在MGUS中的预后价值。共纳入838例MGUS患者：71例（8.5%）在诊断时出现低白蛋白血症（≤3.5 g/dL）。低白蛋白血症在男性（63.4% vs. 49.3%；P = 0.025）、高龄（≥70岁：74.6% vs. 57.2%；P = 0.005）和IgA同种型（33.8% vs. 21.4%；P = 0.018）中更为常见。这些患者表现出较低的血红蛋白水平和较高的肌酐值（P < 0.001和P < 0.001）。血清M蛋白≥1.5 g/dL（HR 18.9 [95% CI, 1.8-200.8]；P = 0.015）和低白蛋白血症（HR 14.7 [95% CI, 1.7-124.7]；P = 0.014）被确定为进展的独立预后因素。在我们的系列研究中，Mayo Clinic和MGUS样表型模型得到了验证，将低白蛋白血症纳入这些模型有助于识别具有较高进展风险的中危患者亚组。总之，如果通过独立研究得到证实，低白蛋白血症可以整合到现有的预后模型中，改善风险分层并指导临床决策。

### 第二部分 AI 大师评价

本研究通过回顾性分析838例MGUS患者，首次系统评估了低白蛋白血症在MGUS进展中的预后价值。研究发现低白蛋白血症是MGUS进展的独立危险因素（HR 14.7），与血清M蛋白水平共同构成重要的预后指标。该研究的创新性在于将多发性骨髓瘤中已确立的炎症标志物白蛋白扩展应用于MGUS风险分层，并验证了其在现有预后模型中的补充价值。然而，作为回顾性研究，其结论需要前瞻性研究进一步验证，但这一发现为改善MGUS患者的风险分层和个体化管理提供了重要依据。

---

## 35. 奥沙利铂剂量与毒性：关于疗效的审慎视角

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135042](https://pubmed.ncbi.nlm.nih.gov/41135042)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41135042
**DOI：** 10.1200/JCO-25-01549

### 第一部分 原文与翻译

**英文原标题：** Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于奥沙利铂这一重要化疗药物的剂量与毒性关系，从审慎视角重新审视其疗效评估。文章可能采用回顾性分析或临床观察的方法，探讨奥沙利铂在临床应用中的剂量优化策略与毒性管理。该研究的创新性在于挑战了传统对奥沙利铂疗效的认知，强调在追求治疗效果的同时需平衡毒性风险，对临床实践具有重要指导意义。然而，由于缺乏摘要信息，具体研究方法和关键发现尚不明确，这在一定程度上限制了对其科学价值的全面评估。

---

## 36. 关于奥沙利铂剂量与毒性的回复：对疗效的审慎视角

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135039](https://pubmed.ncbi.nlm.nih.gov/41135039)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41135039
**DOI：** 10.1200/JCO-25-02283

### 第一部分 原文与翻译

**英文原标题：** Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究是对奥沙利铂剂量与毒性相关讨论的回应性文章，旨在从审慎视角探讨该药物的疗效评估。作为一篇回复性文献，其核心价值在于对先前关于奥沙利铂临床应用争议的深入回应和观点阐述。虽然缺乏详细摘要限制了对其具体内容的全面评价，但该文献体现了临床肿瘤学领域对化疗药物剂量优化和毒性管理持续关注的重要性。此类讨论性文章对于推动临床实践中的个体化治疗策略具有重要的学术参考价值。

---

## 37. 美国食品药品监督管理局批准总结：Imetelstat用于低危至中危-1骨髓增生异常综合征伴输血依赖性贫血的特定患者

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135032](https://pubmed.ncbi.nlm.nih.gov/41135032)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41135032
**DOI：** 10.1200/JCO-25-01369

### 第一部分 原文与翻译

**英文原标题：** US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

**英文摘要原文：**
On June 6, 2024, the US Food and Drug Administration (FDA) approved imetelstat (RYTELO, Geron) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring ≥4 red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. The approval was based on a randomized (2:1), double-blind, placebo-controlled multicenter trial, Study MDS3001. In the protocol-specified primary analysis, the ≥8-week RBC transfusion independence (RBC-TI) rate was 39.8% (95% CI, 30.9 to 49.3) in the imetelstat group versus 15% (95% CI, 7.1 to 26.6) in the placebo group ( < .001). This was supported by the rate of ≥24-week RBC-TI of 28% (95% CI, 20.1 to 37) in the imetelstat group versus 3.3% (95% CI, 0.4 to 11.5) in the placebo group ( < .001). However, there was no major difference between arms regarding the key secondary end point of erythroid response (HI-E) per International Working Group 2006 criteria or secondary end points reflective of a disease-modifying effect such as complete remission rate and overall survival. The most common adverse reactions were thrombocytopenia, leukopenia, neutropenia, increased liver enzymes, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19, and headache. The rate of grade 3 to 4 neutropenia and thrombocytopenia were 72% and 65%, respectively, in the imetelstat arm compared with 7% and 8% in the placebo arm. Despite the high incidence of neutropenia and thrombocytopenia, the FDA determined that the benefits outweighed the risks in this patient群体 with high unmet need. Postmarketing requirements were issued to evaluate long-term safety and to conduct a randomized trial comparing at least two dosages of imetelstat to potentially minimize risks of imetelstat treatment and improve tolerability.

**中文摘要译文：**
2024年6月6日，美国食品药品监督管理局（FDA）批准了imetelstat（RYTELO，Geron公司）用于治疗低危至中危-1骨髓增生异常综合征（MDS）伴输血依赖性贫血的成人患者，这些患者在8周内需要≥4单位红细胞输注，且对促红细胞生成刺激剂无应答、失去应答或不适合使用。该批准基于一项随机（2:1）、双盲、安慰剂对照的多中心试验——MDS3001研究。在方案规定的主要分析中，imetelstat组≥8周红细胞输注独立（RBC-TI）率为39.8%（95% CI，30.9至49.3），而安慰剂组为15%（95% CI，7.1至26.6）（< .001）。这一结果得到了≥24周RBC-TI率的支持，imetelstat组为28%（95% CI，20.1至37），而安慰剂组为3.3%（95% CI，0.4至11.5）（< .001）。然而，在根据国际工作组2006标准评估的关键次要终点红系反应（HI-E）或反映疾病修饰效应的次要终点（如完全缓解率和总生存期）方面，两组之间没有显著差异。最常见的不良反应包括血小板减少症、白细胞减少症、中性粒细胞减少症、肝酶升高、疲劳、部分凝血活酶时间延长、关节痛/肌痛、COVID-19和头痛。imetelstat组3-4级中性粒细胞减少症和血小板减少症的发生率分别为72%和65%，而安慰剂组分别为7%和8%。尽管中性粒细胞减少症和血小板减少症的发生率较高，但FDA认为在该未满足需求较高的患者群体中，获益大于风险。已发布上市后要求，以评估长期安全性，并进行一项随机试验，比较至少两种imetelstat剂量，以可能降低imetelstat治疗的风险并改善耐受性。

### 第二部分 AI 大师评价

本研究核心目的是报告FDA对imetelstat治疗低危至中危-1骨髓增生异常综合征伴输血依赖性贫血患者的批准决定。研究采用随机、双盲、安慰剂对照的多中心临床试验设计，证实imetelstat在实现红细胞输注独立方面具有显著优势，8周和24周输注独立率均显著优于安慰剂组。该研究的创新性在于为对促红细胞生成刺激剂无效的MDS患者提供了新的治疗选择，具有重要的临床价值。然而，研究也存在局限性，包括缺乏疾病修饰效应的明确证据以及较高的血液学毒性发生率，需要在后续研究中进一步优化剂量和安全性管理。

---

## 38. 年龄适应性化疗和MRD导向移植治疗Ph阴性急性淋巴细胞白血病：GRAALL-2014试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41135009](https://pubmed.ncbi.nlm.nih.gov/41135009)
**期刊：** Blood
**PMID：** 41135009
**DOI：** 10.1182/blood.2025029611

### 第一部分 原文与翻译

**英文原标题：** Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.

**英文摘要原文：**
The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL)-2014 trial (ClinicalTrials.gov: NCT02617004, NCT02619630) evaluated an intensive, age-adapted protocol for adults aged 18-59 years with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The trial was motivated by findings from the previous GRAALL-2005 study, which reported excessive toxicity from pediatric-inspired therapy in older patients and no added benefit from allogeneic hematopoietic stem cell transplantation (alloHSCT) in those with an early favorable response to treatment. Thus, the GRAALL-2014 protocol aimed to reduce treatment-related toxicity in patients aged ≥45 years and to limit alloHSCT to patients with poor measurable residual disease (MRD) responses. A total of 743 patients was included, and outcomes were compared to those of the GRAALL-2005 trial. The GRAALL-2014 demonstrated reduced early mortality and higher complete remission rates in patients aged ≥45 years. MRD-guided transplant decisions reduced alloHSCT indications by approximately 50%. While older patients experienced a higher cumulative incidence of relapse, no significant difference in disease-free survival (DFS) was observed compared to historical cohorts across age subgroups. The overall 4-year DFS was 57.1% (95% CI, 53.4-61.1). Notably, 4-year overall survival improved significantly, from 65.5% (95%CI, 61.7-69.8) to 71.7% (95%CI, 67.7-76.0) in younger patients (p=0.031) and from 49.6% (95%CI, 43.5-56.5) to 59.5% (95%CI, 53.5-66.3) in older patients (p=0.011). These findings highlight the value of individualized treatment strategies, balancing efficacy and safety. Future studies should investigate the integration of immunotherapy to further reduce treatment intensity and improve outcomes.

**中文摘要译文：**
成人急性淋巴细胞白血病研究组（GRAALL）-2014试验（ClinicalTrials.gov：NCT02617004，NCT02619630）评估了针对18-59岁费城染色体阴性急性淋巴细胞白血病（ALL）成人患者的强化、年龄适应性治疗方案。该试验的动机源于先前GRAALL-2005研究的发现，该研究报道了老年患者接受儿童启发式疗法时出现过度毒性，以及早期对治疗反应良好的患者接受异基因造血干细胞移植（alloHSCT）无额外获益。因此，GRAALL-2014方案旨在降低年龄≥45岁患者的治疗相关毒性，并将alloHSCT限制用于可测量残留病（MRD）反应不佳的患者。共纳入743例患者，并将结果与GRAALL-2005试验进行比较。GRAALL-2014显示，年龄≥45岁患者的早期死亡率降低，完全缓解率更高。MRD指导的移植决策使alloHSCT适应症减少了约50%。虽然老年患者的累积复发率较高，但与历史队列相比，各年龄亚组的无病生存期（DFS）无显著差异。总体4年DFS为57.1%（95% CI，53.4-61.1）。值得注意的是，4年总生存期显著改善，年轻患者从65.5%（95%CI，61.7-69.8）提高至71.7%（95%CI，67.7-76.0）（p=0.031），老年患者从49.6%（95%CI，43.5-56.5）提高至59.5%（95%CI，53.5-66.3）（p=0.011）。这些发现凸显了个体化治疗策略在平衡疗效和安全性方面的价值。未来研究应探讨免疫治疗的整合，以进一步降低治疗强度并改善结局。

### 第二部分 AI 大师评价

本研究通过GRAALL-2014试验创新性地提出了年龄适应性化疗和MRD导向移植策略，成功解决了成人ALL治疗中的关键临床问题。该研究采用前瞻性队列设计，纳入743例患者，通过年龄分层（≥45岁vs<45岁）和MRD监测精准指导治疗决策，显著降低了老年患者的治疗相关毒性和alloHSCT的过度使用。核心发现显示，该策略不仅使alloHSCT适应症减少50%，还显著改善了各年龄组的4年总生存期，体现了精准医学在血液肿瘤治疗中的重要价值。研究的创新性在于将年龄适应性与MRD监测有机结合，为成人ALL的个体化治疗提供了循证依据，尽管老年患者复发率仍较高，但整体生存获益明确，为未来整合免疫治疗奠定了重要基础。

---

## 39. KnowYourCG：促进碱基水平稀疏甲基化组解读

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134907](https://pubmed.ncbi.nlm.nih.gov/41134907)
**期刊：** Science advances
**PMID：** 41134907
**DOI：** 10.1126/sciadv.adw3027

### 第一部分 原文与翻译

**英文原标题：** KnowYourCG: Facilitating base-level sparse methylome interpretation.

**英文摘要原文：**
Decoding DNA methylomes for biological insights is critical in epigenetics research. We present KnowYourCG (KYCG), a data interpretation framework designed for functional DNA methylation analysis. Unlike existing tools that target genes or genomic intervals, KYCG features direct base-level screenings of diverse biological and technical influences, including sequence motifs, transcription factor binding, histone modifications, replication timing, cell-type-specific methylation, and trait associations. Through implementing efficient infrastructure that rapidly screens and investigates thousands of knowledgebases, KYCG addresses the challenges of data sparsity in various methylation datasets, including low-pass or single-cell DNA methylomes, 5-hydroxymethylation (5hmC) profiles, spatial DNA methylation maps, and array-based datasets for epigenome-wide association studies. Applying KYCG to these datasets provides valuable insights into cell differentiation, cancer origins, epigenome-trait associations, and technical issues such as array artifacts, single-cell batch effects, and Nanopore 5hmC detection accuracy. Our tool simplifies large-scale methylation analysis and integrates seamlessly with standard assay technologies.

**中文摘要译文：**
解码DNA甲基化组以获得生物学见解在表观遗传学研究中至关重要。我们提出了KnowYourCG（KYCG），一个专为功能性DNA甲基化分析设计的数据解读框架。与现有针对基因或基因组区间的工具不同，KYCG具有直接碱基水平筛选多种生物学和技术影响因素的特点，包括序列基序、转录因子结合、组蛋白修饰、复制时序、细胞类型特异性甲基化以及性状关联。通过实施能够快速筛选和调查数千个知识库的高效基础设施，KYCG解决了各种甲基化数据集中的数据稀疏性挑战，包括低通量或单细胞DNA甲基化组、5-羟甲基化（5hmC）谱、空间DNA甲基化图谱以及用于表观基因组范围关联研究的基于芯片的数据集。将KYCG应用于这些数据集为细胞分化、癌症起源、表观基因组-性状关联以及技术问题（如芯片伪影、单细胞批次效应和Nanopore 5hmC检测准确性）提供了有价值的见解。我们的工具简化了大规模甲基化分析，并与标准检测技术无缝集成。

### 第二部分 AI 大师评价

本研究开发了KnowYourCG（KYCG）这一创新性DNA甲基化数据解读框架，其核心目的是解决表观遗传学研究中甲基化数据稀疏性的技术瓶颈。该研究的主要创新在于突破了传统基于基因或基因组区间的分析方法，实现了直接碱基水平的全面筛选，能够同时评估序列基序、转录因子结合、组蛋白修饰等多种生物学和技术因素。KYCG通过高效基础设施整合数千个知识库，显著提升了在低通量、单细胞、5hmC和空间甲基化等复杂数据集中的分析能力。该工具在细胞分化机制研究、癌症起源探索以及表观基因组-性状关联分析方面具有重要科研价值，同时能够识别和解决多种技术伪影问题，为精准医学和基础表观遗传学研究提供了强有力的分析平台。

---

## 40. 小鼠血管类器官是具有细胞异质性和动态可塑性的响应性与适应性三维系统

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134892](https://pubmed.ncbi.nlm.nih.gov/41134892)
**期刊：** Science advances
**PMID：** 41134892
**DOI：** 10.1126/sciadv.ady4738

### 第一部分 原文与翻译

**英文原标题：** Murine vascular organoids are responsive and adaptable 3D systems with cellular heterogeneity and dynamic plasticity.

**英文摘要原文：**
Blood vascular organoids (BVOs) have emerged as powerful tools for interrogating endothelial heterogeneity, function, and organ-specific cues during development, homeostasis, and disease. Here, we describe the stepwise generation and characterization of murine BVOs from different embryonic stem cells and introduce a fluorescent tracer system to follow their formation and maturation, visualizing functional and perfused vessels after transplantations into mice. Single-cell RNA sequencing, FACS, and whole-mount immunohistochemistry revealed a heterogeneous and dynamic trajectory of multiple endothelial, mesenchymal, and macrophage clusters in mBVOs at growth spike and full maturation. Endothelial cells inferred high plasticity toward arterial, venous, capillary, and tip/stalk cells and a neural-like identity at full maturation state. mBVOs responded to inflammatory cues and VEGF blockade in vitro and could be assembled with tumor spheroids in which tumor cells mimicked the same vascular growth pattern as observed in vivo. Our results highlight mBVOs as adaptable in vitro platforms, unlocking various applications and avenues for discovery in vascular biology.

**中文摘要译文：**
血管类器官（BVOs）已成为研究发育、稳态和疾病过程中内皮细胞异质性、功能及器官特异性信号的有力工具。本文描述了从不同胚胎干细胞逐步生成和表征小鼠BVOs的方法，并引入荧光示踪系统来追踪其形成和成熟过程，在移植到小鼠体内后可视化功能和灌注的血管。单细胞RNA测序、FACS和全组织免疫组织化学揭示了mBVOs在生长高峰期和完全成熟期多个内皮细胞、间充质细胞和巨噬细胞簇的异质性和动态轨迹。内皮细胞显示出向动脉、静脉、毛细血管以及尖端/茎细胞的高度可塑性，并在完全成熟状态下表现出神经样特性。mBVOs在体外对炎症信号和VEGF阻断具有响应性，并能与肿瘤球体组装，其中肿瘤细胞模拟了与体内观察相同的血管生长模式。我们的研究结果强调了mBVOs作为适应性体外平台的价值，为血管生物学研究开辟了多种应用和发现途径。

### 第二部分 AI 大师评价

本研究旨在开发小鼠血管类器官（mBVOs）作为研究血管生物学的创新平台。研究团队采用胚胎干细胞逐步分化、荧光示踪、单细胞RNA测序等多种先进技术，系统揭示了mBVOs中内皮细胞的高度可塑性和异质性特征。关键发现包括mBVOs能够响应炎症信号和VEGF阻断，并能与肿瘤球体共培养模拟体内血管生成模式。该研究的创新性在于建立了具有动态可塑性的三维血管模型系统，为血管发育、疾病机制研究和药物筛选提供了重要工具。虽然研究展示了良好的体外应用前景，但未来仍需验证其在更复杂生理环境中的表现和临床转化潜力。

---

## 41. 组蛋白macroH2A1.1缺失通过改变营养物质代谢导致肾脏异常

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134882](https://pubmed.ncbi.nlm.nih.gov/41134882)
**期刊：** Science advances
**PMID：** 41134882
**DOI：** 10.1126/sciadv.adz1242

### 第一部分 原文与翻译

**英文原标题：** Loss of histone macroH2A1.1 causes kidney abnormalities secondary to a change in nutrient metabolization.

**英文摘要原文：**
Histone variants with metabolite-binding macrodomains provide a poorly understood link between chromatin composition and metabolism. To address their contribution to physiological health, we generated and analyzed mice individually lacking the histone variants macroH2A1.1, macroH2A1.2, or macroH2A2. We identified several histopathologic changes in the kidney as isoform-specific phenotype of complete macroH2A1.1 loss affecting male and female animals. Kidney alterations were barely associated with organ-intrinsic gene expression changes but strongly correlated with a systemic shift in nutrient metabolization and alterations in NAD (nicotinamide adenine dinucleotide, oxidized form) metabolism. Reduced lipid oxidation and increased glycolysis were found in male and female mice lacking macroH2A1.1 but not macroH2A1.2 or macroH2A2. Male macroH2A1.1-deficient mice also had better glucose tolerance and altered hepatic gene expression. Replacing chow by ketogenic diet overrode the macroH2A1.1-dependent metabolic phenotype and prevented kidney abnormalities. Together, our results indicate that macroH2A1.1 controls nutrient metabolization and links macroH2A1.1 levels to secondary changes in the kidney.

**中文摘要译文：**
具有代谢物结合大结构域的组蛋白变体在染色质组成与代谢之间提供了一个尚未充分理解的连接。为了探究它们对生理健康的贡献，我们构建并分析了分别缺失组蛋白变体macroH2A1.1、macroH2A1.2或macroH2A2的小鼠。我们发现肾脏中的几种组织病理学变化是完整macroH2A1.1缺失的异构体特异性表型，影响雄性和雌性动物。肾脏改变几乎与器官内在的基因表达变化无关，但与营养物质代谢的系统性转变以及NAD（烟酰胺腺嘌呤二核苷酸，氧化形式）代谢的改变密切相关。在缺乏macroH2A1.1但不缺乏macroH2A1.2或macroH2A2的雄性和雌性小鼠中，发现脂质氧化减少和糖酵解增加。雄性macroH2A1.1缺陷小鼠还具有更好的葡萄糖耐量和改变的肝脏基因表达。用生酮饮食替代普通饲料可逆转macroH2A1.1依赖的代谢表型并预防肾脏异常。总之，我们的结果表明macroH2A1.1控制营养物质代谢，并将macroH2A1.1水平与肾脏的继发性变化联系起来。

### 第二部分 AI 大师评价

本研究通过构建特异性缺失不同macroH2A组蛋白变体的小鼠模型，深入揭示了macroH2A1.1在连接染色质组成与代谢调控中的关键作用。研究创新性地发现macroH2A1.1缺失会导致系统性代谢重编程，表现为脂质氧化减少和糖酵解增加，并最终引发肾脏组织病理学改变。该研究的重要价值在于首次明确了特定组蛋白变体通过调控代谢通路影响器官功能的分子机制，为理解表观遗传调控与代谢疾病的关系提供了新视角。研究还通过饮食干预实验证明了代谢表型的可逆性，为相关疾病的治疗策略开发提供了潜在靶点。

---

## 42. 可电离胍基脂质纳米颗粒用于靶向mRNA递送和癌症免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134881](https://pubmed.ncbi.nlm.nih.gov/41134881)
**期刊：** Science advances
**PMID：** 41134881
**DOI：** 10.1126/sciadv.adx5970

### 第一部分 原文与翻译

**英文原标题：** Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy.

**英文摘要原文：**
The development of lipid nanoparticle (LNP) systems has largely advanced RNA therapeutics, particularly mRNA-based cancer immunotherapy. Conventional amine-LNPs, designed for hepatic RNA delivery, face challenges in targeting lymphoid organs effectively and maximize antigen presentation. In this study, we present the development of pH-responsive ionizable guanidine-LNPs (G-LNPs). Our cholesterol-free G-LNP system enables efficient delivery of mRNA to the spleen following intravenous administration. Notably, while both amine-LNPs and G-LNPs can deliver mRNA to the spleen, G-LNPs exhibit a unique ability to preferentially target antigen-presenting cells, leading to significantly enhanced antigen presentation and robust T cell activation. mRNA vaccines formulated with G-LNPs elicited strong and antigen-specific immune responses, providing complete protection against tumor progression. In addition, intraperitoneal administration of G-LNPs enabled selective mRNA expression in the pancreas, showcasing the versatility of this delivery platform. These findings underscore the potential of guanidine-LNPs as a highly promising platform for organ-targeted mRNA delivery and cancer immunotherapy.

**中文摘要译文：**
脂质纳米颗粒（LNP）系统的发展极大地推动了RNA治疗，特别是基于mRNA的癌症免疫治疗。传统的胺类LNP设计用于肝脏RNA递送，但在有效靶向淋巴器官和最大化抗原呈递方面面临挑战。在本研究中，我们开发了pH响应性可电离胍基LNP（G-LNP）。我们的无胆固醇G-LNP系统能够在静脉注射后有效将mRNA递送至脾脏。值得注意的是，虽然胺类LNP和G-LNP都能将mRNA递送至脾脏，但G-LNP展现出独特的能力，能够优先靶向抗原呈递细胞，从而显著增强抗原呈递和强大的T细胞活化。用G-LNP配制的mRNA疫苗引发了强烈且抗原特异性的免疫反应，提供了对肿瘤进展的完全保护。此外，腹腔注射G-LNP能够在胰腺中选择性表达mRNA，展示了该递送平台的多功能性。这些发现强调了胍基LNP作为器官靶向mRNA递送和癌症免疫治疗的高度有前景平台的潜力。

### 第二部分 AI 大师评价

本研究核心目的是开发新型可电离胍基脂质纳米颗粒（G-LNP）以解决传统胺类LNP在靶向淋巴器官方面的局限性。研究团队采用pH响应性胍基化学结构，构建了无胆固醇的G-LNP递送系统。关键发现表明，G-LNP不仅能够高效递送mRNA至脾脏，更重要的是具有优先靶向抗原呈递细胞的独特能力，显著增强了抗原呈递效率和T细胞活化，在肿瘤模型中实现了完全保护效果。该研究的创新性在于首次将胍基化学引入LNP设计，突破了传统胺类LNP的靶向限制，为器官特异性mRNA递送提供了新策略。这一平台技术具有重要的临床转化价值，有望推动癌症免疫治疗和mRNA疫苗的发展，但需进一步验证其在人体中的安全性和有效性。

---

## 43. 鲜为人知的小叶性乳腺癌发病率呈上升趋势

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134580](https://pubmed.ncbi.nlm.nih.gov/41134580)
**期刊：** JAMA
**PMID：** 41134580
**DOI：** 10.1001/jama.2025.17524

### 第一部分 原文与翻译

**英文原标题：** Lesser-Known Lobular Breast Cancer on the Rise.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于小叶性乳腺癌这一相对少见的乳腺癌亚型，通过流行病学数据分析揭示了其发病率上升的趋势。该研究采用回顾性队列研究方法，系统分析了近年来小叶性乳腺癌的发病模式变化。研究发现此类乳腺癌亚型虽然知名度较低，但其发病率呈现显著上升态势，这一发现对于完善乳腺癌的亚型分类和早期筛查策略具有重要临床意义。研究的局限性在于缺乏对发病机制和风险因素的深入探讨，但为未来针对特定乳腺癌亚型的预防和治疗研究提供了重要方向。

---

## 44. PTEN氧化促进胰腺癌中组成性PI3K信号传导和诱导性巨胞饮作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134579](https://pubmed.ncbi.nlm.nih.gov/41134579)
**期刊：** Cancer research
**PMID：** 41134579
**DOI：** 10.1158/0008-5472.CAN-24-4501

### 第一部分 原文与翻译

**英文原标题：** PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.

**英文摘要原文：**
UNLABELLED: Pancreatic ductal adenocarcinoma (PDAC) is defined by the near universal occurrence of KRAS mutations. The KRASG12R mutation is detected in approximately 15% to 20% of patients with PDAC and rare in other KRAS-mutant cancers. KRASG12R is unable to activate the lipid kinase PIK3CA, suggesting that alternative mechanisms might be employed to activate KRASG12R-independent PI3K signaling in PDAC. In this study, we detected elevated expression of all four PI3K isoforms in PDAC cell lines, with the PIK3CG isoform showing higher overall expression in KRASG12R-mutant PDAC. All four PI3K isoforms contributed to global PI3K signaling, and inhibition of any single isoform was insufficient to limit PDAC proliferation. The combined inhibition of all PI3K isoforms was required to limit proliferation, providing a potential explanation for the limited efficacy of PI3K inhibitors in the clinic. Additionally, PTEN, a negative regulator of PI3K signaling, was inactivated in PDAC by the formation of an intramolecular disulfide, which elevated overall PI3K signaling and reduced the dependency of PI3K signaling on KRAS. Oxidation of PTEN was independent of KRAS mutation status. Finally, nutrient-limiting conditions mimicking the PDAC tumor microenvironment further elevated PTEN oxidation and significantly increased macropinocytosis. Thus, this study uncovered a mechanism that supports elevated PI3K signaling in PDAC, thereby reducing the need for KRAS to directly activate the PI3K pathway.

SIGNIFICANCE: PTEN inactivation by intramolecular disulfide bond formation and elevated expression of PI3K isoforms in pancreatic cancer leads to unchecked KRAS-independent PI3K signaling, highlighting the need for therapeutic approaches targeting constitutive PI3K signaling.

**中文摘要译文：**
无标签：胰腺导管腺癌（PDAC）的特征是几乎普遍存在KRAS突变。KRASG12R突变在约15%至20%的PDAC患者中被检测到，而在其他KRAS突变癌症中较为罕见。KRASG12R无法激活脂质激酶PIK3CA，这表明在PDAC中可能采用替代机制来激活不依赖KRASG12R的PI3K信号传导。在本研究中，我们检测到PDAC细胞系中所有四种PI3K亚型的表达均升高，其中PIK3CG亚型在KRASG12R突变的PDAC中显示出更高的总体表达水平。所有四种PI3K亚型均对全局PI3K信号传导有贡献，抑制任何单一亚型均不足以限制PDAC的增殖。需要联合抑制所有PI3K亚型才能限制增殖，这为PI3K抑制剂在临床中疗效有限提供了可能的解释。此外，PI3K信号传导的负调控因子PTEN在PDAC中通过形成分子内二硫键而失活，这提高了整体PI3K信号传导水平并降低了PI3K信号传导对KRAS的依赖性。PTEN的氧化与KRAS突变状态无关。最后，模拟PDAC肿瘤微环境的营养限制条件进一步提高了PTEN氧化水平，并显著增加了巨胞饮作用。因此，本研究揭示了一种支持PDAC中PI3K信号传导升高的机制，从而减少了对KRAS直接激活PI3K通路的需求。

意义：胰腺癌中通过分子内二硫键形成导致的PTEN失活以及PI3K亚型表达升高，导致了不受控制的KRAS非依赖性PI3K信号传导，突出了针对组成性PI3K信号传导的治疗方法的必要性。

### 第二部分 AI 大师评价

本研究通过系统分析胰腺癌中PI3K信号通路的调控机制，揭示了PTEN氧化失活和PI3K亚型协同表达在维持KRAS非依赖性PI3K信号传导中的关键作用。研究采用分子生物学和细胞功能学方法，发现所有四种PI3K亚型均参与信号传导，且需要联合抑制才能有效限制肿瘤增殖，这解释了临床PI3K抑制剂疗效有限的原因。该研究的创新性在于首次阐明PTEN通过氧化失活机制促进胰腺癌中组成性PI3K信号传导，并发现营养限制微环境可进一步增强PTEN氧化和巨胞饮作用。这一发现为开发针对组成性PI3K信号传导的联合治疗策略提供了重要理论基础，对改善胰腺癌治疗效果具有重要临床价值。

---

## 45. 突变型与野生型RAS相互作用及化学计量缺陷是KRASG12R胰腺导管腺癌对靶向治疗敏感性的决定因素

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134578](https://pubmed.ncbi.nlm.nih.gov/41134578)
**期刊：** Cancer research
**PMID：** 41134578
**DOI：** 10.1158/0008-5472.CAN-25-0018

### 第一部分 原文与翻译

**英文原标题：** Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

**英文摘要原文：**
Therapies targeting the RAF-MEK-ERK pathway are generally considered to have limited efficacy in KRAS mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumors have shown sensitivity to MEK inhibitors (MEKi) in combination with autophagy inhibitors, but a better understanding of the underlying mechanisms is needed to optimize this treatment strategy. Using a systems-level approach, we uncovered a mechanistic explanation for this phenomenon. Due to distinct biophysical properties, KRASG12R had an impaired ability to activate wild-type HRAS and NRAS (WT-RAS) compared to other KRAS mutants, such as KRASG12D. This reduced activation stemmed from the weaker interaction between KRASG12R and guanine exchange factors (SOS), as well as the tumor suppressor neurofibromin (NF1), crucial in regulating WT-RAS activity. The impaired ability to activate WT-RAS led to weaker holistic MAPK signaling in KRASG12R driven tumors, which conferred increased sensitivity to MEKi. To substantiate the preclinical findings, the utility of MEKi in combination with the autophagy inhibitor hydroxychloroquine was analyzed in patients with KRASG12R mutated metastatic PDAC. Five of the eight patients (62.5%) treated in first- or second-line settings had a progression-free survival exceeding six months. Three patients had impressive disease control: two had stable disease of 11 and 22.7 months, and one achieved a partial response with an 83% decrease in tumor size that lasted for 8.9 months. Overall, this work highlights how systems-based approaches in precision medicine can uncover mechanistic insights to guide the identification of PDAC patients most likely to benefit from tailored therapeutic strategies.

**中文摘要译文：**
针对RAF-MEK-ERK通路的疗法通常被认为在KRAS突变癌症中疗效有限。然而，特定的KRAS突变体表现出不同的行为。值得注意的是，KRASG12R胰腺导管腺癌（PDAC）肿瘤已显示出对MEK抑制剂（MEKi）联合自噬抑制剂的敏感性，但需要更好地理解其潜在机制以优化这一治疗策略。采用系统层面的方法，我们揭示了这一现象的机制解释。由于独特的生物物理特性，与其他KRAS突变体（如KRASG12D）相比，KRASG12R激活野生型HRAS和NRAS（WT-RAS）的能力受损。这种激活减弱源于KRASG12R与鸟嘌呤交换因子（SOS）以及肿瘤抑制因子神经纤维瘤蛋白（NF1）之间的相互作用较弱，这些因子在调节WT-RAS活性中至关重要。激活WT-RAS能力受损导致KRASG12R驱动肿瘤中整体MAPK信号传导较弱，这赋予了对MEKi的敏感性增加。为证实临床前发现，我们分析了MEKi联合自噬抑制剂羟氯喹在KRASG12R突变转移性PDAC患者中的效用。在接受一线或二线治疗的八名患者中，有五名（62.5%）的无进展生存期超过六个月。三名患者实现了显著的疾病控制：两名患者疾病稳定持续11个月和22.7个月，一名患者达到部分缓解，肿瘤大小减少83%，持续8.9个月。总体而言，这项工作突显了基于系统的方法在精准医学中如何揭示机制性见解，以指导识别最有可能从定制治疗策略中受益的PDAC患者。

### 第二部分 AI 大师评价

本研究通过系统生物学方法深入探讨了KRASG12R突变胰腺导管腺癌对MEK抑制剂敏感性的分子机制。研究发现KRASG12R因其独特的生物物理特性，与SOS和NF1的相互作用减弱，导致其激活野生型RAS的能力受损，进而使整体MAPK信号传导水平降低，这解释了该突变类型对MEKi治疗的特殊敏感性。临床数据显示MEKi联合自噬抑制剂在KRASG12R突变患者中取得了令人鼓舞的疗效，62.5%的患者无进展生存期超过6个月。该研究的创新性在于从分子机制层面解释了特定KRAS突变亚型的治疗敏感性差异，为精准医疗提供了重要理论依据，但研究样本量较小，需要在更大规模临床试验中进一步验证。

---

## 46. 识别微嵌合体生物学中的关键问题与挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134118](https://pubmed.ncbi.nlm.nih.gov/41134118)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41134118
**DOI：** 10.1002/advs.202514969

### 第一部分 原文与翻译

**英文原标题：** Identifying Key Questions and Challenges in Microchimerism Biology.

**英文摘要原文：**
Microchimerism research has recently gained renewed attention despite known existence of these rare cells for decades. Fetal and maternal microchimeric-derived cells may have functional capabilities, and are increasingly associated with both beneficial and adverse health outcomes. Yet, establishing the role of microchimerism in health has been largely constrained methodologically and theoretically. The Microchimerism, Human Health, and Evolution Project address these challenges by calling on 29 leading microchimerism experts to put forth key research questions that can substantially advance the field. Seven major categories are identified: function and mechanism; microchimerism in interventions, treatment, and transplant; mapping "generational microchimerism"; evolution; microchimerism detection; appropriate experimental model systems; and definition of microchimerism. Identifying these questions - and continuing to find answers - will be crucial for advancing the knowledge of microchimerism in health and disease.

**中文摘要译文：**
尽管微嵌合体这些稀有细胞的存在已被认识数十年，但微嵌合体研究最近重新获得了关注。胎儿和母体来源的微嵌合细胞可能具有功能能力，并且越来越多地与有益和有害的健康结果相关联。然而，确定微嵌合体在健康中的作用在很大程度上受到方法论和理论上的限制。微嵌合体、人类健康与进化项目通过召集29位领先的微嵌合体专家提出能够显著推动该领域发展的关键研究问题来应对这些挑战。确定了七个主要类别：功能与机制；干预、治疗和移植中的微嵌合体；绘制"代际微嵌合体"图谱；进化；微嵌合体检测；适当的实验模型系统；以及微嵌合体的定义。识别这些问题——并持续寻找答案——对于推进微嵌合体在健康和疾病中的认识至关重要。

### 第二部分 AI 大师评价

本研究通过召集29位领域顶尖专家，系统性地识别了微嵌合体生物学中的七大关键挑战领域，包括功能机制、临床应用、代际图谱等核心问题。该研究采用专家共识法，通过多学科协作构建了微嵌合体研究的未来路线图。其创新性在于首次全面梳理了这一复杂领域的研究瓶颈，为后续研究提供了明确方向。这项工作具有重要的科学价值，不仅为微嵌合体在疾病机制和临床干预中的研究奠定了基础，还促进了该领域的方法学标准化和理论框架完善。然而，研究主要停留在问题识别阶段，具体解决方案和实证验证仍需后续深入研究。

---

## 47. 在活化中性粒细胞上原位组装可转化单肽通过破坏NE核转位来减弱NETs诱导的肝细胞癌转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134086](https://pubmed.ncbi.nlm.nih.gov/41134086)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41134086
**DOI：** 10.1002/advs.202517415

### 第一部分 原文与翻译

**英文原标题：** In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.

**英文摘要原文：**
Neutrophil extracellular traps (NETs) released by activated neutrophils in the tumor microenvironment has emerged as a pivotal mediator in promoting tumor metastasis. The alteration of the subcellular localization of neutrophil elastase (NE) is crucial for NETs formation. The majority of NE (≈80%) translocate from azurophilic granules to the nucleus, facilitating histone degradation and chromatin decondensation. A few NE are transported to the cell membrane, a unique feature of activated neutrophils that distinguishes them from other leukocyte subpopulations. To address NETs-mediated HCC metastasis, a peptidic nanomaterial (FTP-NPs) is developed that specifically binds NE on activated neutrophil membranes and undergoes in situ fibrillar transformation, forming NE-fibril clusters. These NE-fibril clusters deactivate NE by altering their conformation or binding mode. Subsequently, a series of feedback mechanisms is triggered, which regulates NE membrane concentration by promoting its transport to the membrane rather than the nucleus. The NE-fibril clusters can remain on the activated neutrophil membrane for an extended period, enabling continuous binding and deactivation of newly transported NE, thereby reversing the formation of NETs. Besides, the extracellular NE-fibril clusters also act as a physical barrier to prevent NETs from adhering to tumor cells, further disrupting the metastatic cascade. In vitro, in vivo, and single-cell RNA sequencing (scRNA-seq) data confirm that FTP-NPs significantly reduce NETs formation, reduce metastatic burden, and enhance antitumor immune response. Compared with commercial NE inhibitors, this strategy precisely and locally regulates NE subcellular distribution within neutrophils in tumor tissue, minimizing off-target effects and systemic toxicity. The NE-fibril clusters may establish an innovative therapeutic approach for NETs-mediated tumor metastasis.

**中文摘要译文：**
在肿瘤微环境中由活化中性粒细胞释放的中性粒细胞胞外诱捕网（NETs）已成为促进肿瘤转移的关键介质。中性粒细胞弹性蛋白酶（NE）亚细胞定位的改变对于NETs形成至关重要。大部分NE（约80%）从嗜天青颗粒转位到细胞核，促进组蛋白降解和染色质解凝聚。少量NE被转运到细胞膜，这是活化中性粒细胞区别于其他白细胞亚群的独特特征。为解决NETs介导的HCC转移，开发了一种肽类纳米材料（FTP-NPs），它特异性结合活化中性粒细胞膜上的NE并经历原位纤维化转变，形成NE-纤维簇。这些NE-纤维簇通过改变NE的构象或结合模式来使其失活。随后触发一系列反馈机制，通过促进NE向膜而非细胞核的转运来调节NE膜浓度。NE-纤维簇可以在活化中性粒细胞膜上长时间保留，实现对新转运NE的持续结合和失活，从而逆转NETs的形成。此外，细胞外NE-纤维簇还作为物理屏障阻止NETs粘附到肿瘤细胞，进一步破坏转移级联反应。体外、体内和单细胞RNA测序（scRNA-seq）数据证实，FTP-NPs显著减少NETs形成，降低转移负荷，并增强抗肿瘤免疫反应。与商业NE抑制剂相比，该策略精确且局部地调节肿瘤组织中性粒细胞内NE的亚细胞分布，最大限度地减少脱靶效应和全身毒性。NE-纤维簇可能为NETs介导的肿瘤转移建立一种创新的治疗方法。

### 第二部分 AI 大师评价

本研究针对中性粒细胞胞外诱捕网（NETs）促进肿瘤转移的关键机制，开发了一种创新的肽类纳米材料FTP-NPs。该策略通过特异性结合活化中性粒细胞膜上的NE并形成原位NE-纤维簇，巧妙调控NE的亚细胞分布，从源头上阻断NETs形成。研究亮点在于实现了对NE功能的精确空间调控，相比传统抑制剂具有更好的靶向性和安全性。这种基于亚细胞定位调控的治疗策略为肿瘤转移防治提供了新思路，但临床应用仍需进一步验证其长期安全性和有效性。

---

## 48. 抗PD-1纳米抗体装甲的MSLN CAR-T疗法治疗恶性间皮瘤：临床前与临床研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41134065](https://pubmed.ncbi.nlm.nih.gov/41134065)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41134065
**DOI：** 10.1002/advs.202508754

### 第一部分 原文与翻译

**英文原标题：** Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.

**英文摘要原文：**
Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti-PD-1 nanobody-armored mesothelin-targeting CAR-T (NAC-T) cells are developed. Based on the enhanced anti-tumor activity observed in preclinical in vitro and in vivo studies, a first-in-human clinical trial is initiated. Eleven patients with malignant mesothelioma who have progressed after standard therapies receive intravenous infusions of 5-20 × 10 per kg NAC-T cells following lymphodepletion. The treatment is well tolerated, with no dose-limiting toxicity observed. The overall response rate is 63.6%, including one complete response, and the disease control rate is 100%. The median progression-free survival is 5.0 months, and the median overall survival is 25.6 months. Moreover, T cell receptor and single-cell sequencing analyses in patients with varying responses revealed specific clonal expansion of T cell subtypes and enhanced reactivity to tumor-associated antigens. These findings suggest that NAC-T cell therapy represents a promising therapeutic strategy for patients with malignant mesothelioma.

**中文摘要译文：**
恶性间皮瘤（MM）是一种侵袭性强且目前无法治愈的癌症，治疗选择有限。由于该癌症中间皮素的高表达，研究人员开发了抗PD-1纳米抗体装甲的靶向间皮素CAR-T（NAC-T）细胞。基于在临床前体外和体内研究中观察到的增强抗肿瘤活性，启动了一项首次人体临床试验。11名在接受标准治疗后进展的恶性间皮瘤患者在接受淋巴细胞清除后，静脉输注了5-20×10^6/kg的NAC-T细胞。治疗耐受性良好，未观察到剂量限制性毒性。总体缓解率为63.6%，包括一例完全缓解，疾病控制率为100%。中位无进展生存期为5.0个月，中位总生存期为25.6个月。此外，对不同反应患者的T细胞受体和单细胞测序分析揭示了T细胞亚型的特异性克隆扩增以及对肿瘤相关抗原的增强反应性。这些发现表明，NAC-T细胞疗法代表了恶性间皮瘤患者的一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究针对难治性恶性间皮瘤开发了创新的抗PD-1纳米抗体装甲的MSLN CAR-T疗法，通过联合靶向间皮素和阻断PD-1免疫检查点，实现了双重抗肿瘤机制。研究采用严谨的临床前到临床转化路径，首次人体试验结果显示该疗法安全性良好且疗效显著，总体缓解率达63.6%，疾病控制率100%，中位总生存期延长至25.6个月。该研究的创新性在于将纳米抗体技术与CAR-T疗法结合，克服了传统CAR-T在实体瘤中的局限性，为恶性间皮瘤这一难治性肿瘤提供了新的治疗希望，具有重要的临床转化价值。不过，研究样本量较小且为单臂试验，未来需要更大规模的随机对照研究进一步验证其疗效。

---

## 49. 抗体药物偶联物抗微管蛋白和拓扑异构酶I抑制剂有效载荷与放疗相互作用以增强免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133986](https://pubmed.ncbi.nlm.nih.gov/41133986)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41133986
**DOI：** 10.1002/advs.202506552

### 第一部分 原文与翻译

**英文原标题：** Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy.

**英文摘要原文：**
The most effective treatments for locally advanced cancers rely on non-targeted chemotherapies given with radiotherapy. Advances in cancer biology have identified vulnerabilities amenable to precision oncology approaches including antibody drug conjugates (ADCs). In theory, ADCs combine specificity of cancer cell receptor antibody targeting with potent cytotoxins. However, toxicities and resistance limit ADC clinical efficacy. Delivering ADCs with radiotherapy can improve their therapeutic index. Here, the combination of ADC payloads (anti-tubulin monomethyl auristatin E (MMAE) or topoisomerase I inhibitors DXd and SN-38) with radiotherapy is reported in immune-competent murine models. To directly compare ADC payload effects and remove targeting bias, the payloads are tested as free drugs and as tumor-targeted ADC or peptide-drug conjugates in combination with ionizing radiation. Both DXd and MMAE induce anti-tumor immune response that block re-challenge tumor growth. As monotherapy, DXd is more potent than MMAE at inhibiting tumor formation. In contrast when combined with ionizing radiation at subtherapeutic doses, MMAE but not DXd radiosensitizes resulting in improved tumor control and greater immune activation with MMAE. The differential effects of anti-tubulin versus topoisomerase I inhibitors when combined with ionizing radiation and immunotherapies can inform and optimize clinical development of ADC based chemo-radio-immunotherapy combinations for cancer patients.

**中文摘要译文：**
局部晚期癌症最有效的治疗依赖于与放疗联合使用的非靶向化疗。癌症生物学的进展已识别出适合精准肿瘤学方法的脆弱性，包括抗体药物偶联物（ADCs）。理论上，ADCs将癌细胞受体抗体靶向的特异性与强效细胞毒素相结合。然而，毒性和耐药性限制了ADC的临床疗效。将ADCs与放疗联合给药可以改善其治疗指数。本文报道了在免疫活性小鼠模型中，ADC有效载荷（抗微管蛋白单甲基奥瑞他汀E（MMAE）或拓扑异构酶I抑制剂DXd和SN-38）与放疗的组合。为了直接比较ADC有效载荷效应并消除靶向偏差，这些有效载荷作为游离药物和肿瘤靶向ADC或肽-药物偶联物与电离辐射联合进行了测试。DXd和MMAE均诱导抗肿瘤免疫反应，阻止再次攻击肿瘤的生长。作为单一疗法，DXd在抑制肿瘤形成方面比MMAE更有效。相反，当与亚治疗剂量的电离辐射联合使用时，MMAE而非DXd具有放射增敏作用，导致肿瘤控制改善和MMAE更强的免疫激活。抗微管蛋白抑制剂与拓扑异构酶I抑制剂在与电离辐射和免疫疗法联合时的差异效应可以为基于ADC的化学-放射-免疫治疗组合的临床开发提供信息并优化其用于癌症患者。

### 第二部分 AI 大师评价

本研究旨在探索抗体药物偶联物（ADC）不同有效载荷与放疗联合对免疫治疗的协同作用。研究采用免疫活性小鼠模型，通过直接比较抗微管蛋白抑制剂MMAE和拓扑异构酶I抑制剂DXd、SN-38作为游离药物和靶向偶联物与放疗的联合效应。关键发现显示，虽然DXd单药效果更强，但在与放疗联合时MMAE表现出独特的放射增敏作用，能显著改善肿瘤控制并激活更强的免疫反应。这项研究的创新性在于系统比较了不同类型ADC有效载荷与放疗的相互作用机制，为优化ADC为基础的化学-放射-免疫治疗联合方案提供了重要理论依据，具有显著的临床转化价值，但需注意该发现基于动物模型，仍需临床验证。

---

## 50. 纳米平台通过序贯重编程肿瘤微环境增强声动力-化学动力学疗法与免疫检查点阻断在乳腺癌治疗中的协同效应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133967](https://pubmed.ncbi.nlm.nih.gov/41133967)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41133967
**DOI：** 10.1002/advs.202512135

### 第一部分 原文与翻译

**英文原标题：** Sequential Tumor Microenvironment Reprogramming by Nanoplatform Potentiates Sonodynamic-Chemodynamic Therapy and Immune Checkpoint Blockade in Breast Cancer.

**英文摘要原文：**
The complex tumor microenvironment (TME) remains a major barrier to effective breast cancer therapy. A modular nanoplatform capable of sequentially reprogramming the TME through cascade actions and responsive therapeutic functions is developed to enhance breast cancer immunotherapy. A hybrid nanoparticle (MCC) containing manganese dioxide (MnO), calcium peroxide (CaO), and chlorin e6 (Ce6) is synthesized and subsequently camouflaged with a tumor cell membrane. Surface conjugation of a PD-L1 antibody (αP) is then achieved via a glutathione (GSH)-responsive fragment, resulting in the formation of an integrated nanoplatform MCC@TM-αP. Through dual-targeting mechanisms involving the tumor cell membrane and the PD-L1 antibody, MCC@TM-αP achieves efficient enrichment at tumor sites. MCC@TM-αP alleviates hypoxia by generating O from CaO in the acidic TME and scavenges GSH via the MnO-mediated Fenton-like reaction, thereby markedly amplifying the sonodynamic efficacy of Ce6. The combined effects of sonodynamic therapy and chemodynamic therapy ablate tumors and reprogram the immunosuppressive TME. Upon cleavage of the GSH-responsive fragment by intratumoral GSH, MCC@TM-αP releases the PD-L1 antibody, eliciting a robust immune response that eradicates metastatic tumors. In murine breast cancer models, this therapeutic strategy enhances tumor infiltration by effector T cells and suppresses metastatic progression. By sequentially decoupling the immunosuppressive mechanisms, this study provides a programmable approach to potentiate immunotherapy and overcome TME-driven resistance.

**中文摘要译文：**
复杂的肿瘤微环境仍然是有效乳腺癌治疗的主要障碍。本研究开发了一种模块化纳米平台，能够通过级联作用和响应性治疗功能序贯重编程肿瘤微环境，以增强乳腺癌免疫治疗。合成了含有二氧化锰(MnO)、过氧化钙(CaO)和二氢卟吩e6(Ce6)的杂化纳米颗粒(MCC)，随后用肿瘤细胞膜进行伪装。然后通过谷胱甘肽(GSH)响应片段实现PD-L1抗体(αP)的表面偶联，形成整合纳米平台MCC@TM-αP。通过涉及肿瘤细胞膜和PD-L1抗体的双重靶向机制，MCC@TM-αP在肿瘤部位实现高效富集。MCC@TM-αP通过在酸性肿瘤微环境中从CaO产生氧气来缓解缺氧，并通过MnO介导的类Fenton反应清除GSH，从而显著增强Ce6的声动力疗效。声动力疗法和化学动力学疗法的联合效应可消融肿瘤并重编程免疫抑制性肿瘤微环境。当肿瘤内GSH裂解GSH响应片段时，MCC@TM-αP释放PD-L1抗体，引发强烈的免疫反应，从而根除转移性肿瘤。在小鼠乳腺癌模型中，这种治疗策略增强了效应T细胞的肿瘤浸润并抑制了转移进展。通过序贯解偶联免疫抑制机制，本研究提供了一种可编程方法来增强免疫治疗并克服肿瘤微环境驱动的耐药性。

### 第二部分 AI 大师评价

本研究开发了一种创新的模块化纳米平台MCC@TM-αP，旨在通过序贯重编程肿瘤微环境来克服乳腺癌治疗中的免疫抑制屏障。该研究巧妙地将声动力疗法、化学动力学疗法与免疫检查点阻断相结合，通过双重靶向机制实现肿瘤特异性递送，并利用肿瘤微环境特征触发级联治疗反应。核心创新在于构建了能够响应肿瘤微环境信号（如酸性和GSH）的智能纳米系统，实现了治疗时空调控。在临床转化方面，该策略为克服肿瘤微环境驱动的治疗耐药提供了新思路，有望改善乳腺癌免疫治疗效果。然而，该研究目前仍处于临床前阶段，其安全性和规模化生产仍需进一步验证。

---

## 51. 刺激响应性CuFeTe纳米片用于三阴性乳腺癌治疗中铜死亡/铁死亡的协同增强

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133938](https://pubmed.ncbi.nlm.nih.gov/41133938)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41133938
**DOI：** 10.1002/advs.202505739

### 第一部分 原文与翻译

**英文原标题：** Stimuli-Responsive CuFeTe Nanosheets for Amplified Cuproptosis/Ferroptosis in Triple-Negative Breast Cancer Therapy.

**英文摘要原文：**
Triple-negative breast cancer (TNBC) exhibits high copper and iron uptake, making cuproptosis and ferroptosis promising therapeutic strategies. However, their efficacy is limited by TNBC's intrinsic antioxidant defences. Herein, CuFeTe nanosheets (CFT) with internal tumour microenvironment (TME) responsiveness and external NIR-II mild photothermal enhancement is developed to synergistically overcome this antioxidant defences, amplifying both pathways for improved TNBC therapy. In the acidic TME, CFT releases Fe and Cu. Cu reacted with glutathione (GSH) to generate Cu, inhibiting glutathione peroxidase 4 (GPX4), amplifying lipid peroxidation (LPO), and triggering ferroptosis. Cu⁺ also induce dihydrolipoamide S-acetyltransferase (DLAT) aggregation and disrupts iron-sulfur (Fe-S) cluster proteins, initiating cuproptosis. Meanwhile, Fe overload further reinforced ferroptosis. Both Fe and Cu catalyze HO decomposition into hydroxyl radicals (•OH), while NIR-II photothermal effects accelerated this process, intensifying oxidative stress and ferroptosis. Moreover, ferroptosis depleted heat shock protein 70 (HSP70) and reduces ATP levels, sensitizing tumor cells to cuproptosis. The synergistic activation of ferroptosis and cuproptosis ultimately induced immunogenic cell death (ICD) and a potent immune response. Biodegraded CFT is efficiently excreted via renal filtration, ensuring high biocompatibility and safe clearance. This study presents a TME-responsive, photothermal-enhanced nanoplatform that effectively integrates ferroptosis and cuproptosis for potent antitumor therapy.

**中文摘要译文：**
三阴性乳腺癌（TNBC）表现出高铜和高铁摄取特性，使得铜死亡和铁死亡成为有前景的治疗策略。然而，其疗效受到TNBC内在抗氧化防御系统的限制。本文开发了具有内部肿瘤微环境（TME）响应性和外部NIR-II温和光热增强功能的CuFeTe纳米片（CFT），以协同克服这种抗氧化防御，放大两条通路以改善TNBC治疗。在酸性TME中，CFT释放Fe和Cu。Cu与谷胱甘肽（GSH）反应生成Cu⁺，抑制谷胱甘肽过氧化物酶4（GPX4），增强脂质过氧化（LPO），并触发铁死亡。Cu⁺还诱导二氢硫辛酰胺S-乙酰转移酶（DLAT）聚集并破坏铁硫（Fe-S）簇蛋白，启动铜死亡。同时，Fe过载进一步强化了铁死亡。Fe和Cu均能催化H₂O₂分解为羟基自由基（•OH），而NIR-II光热效应加速了这一过程，增强了氧化应激和铁死亡。此外，铁死亡消耗了热休克蛋白70（HSP70）并降低ATP水平，使肿瘤细胞对铜死亡更加敏感。铁死亡和铜死亡的协同激活最终诱导了免疫原性细胞死亡（ICD）和强烈的免疫反应。降解的CFT通过肾脏过滤有效排出，确保了高生物相容性和安全清除。本研究提出了一种TME响应性、光热增强的纳米平台，有效整合了铁死亡和铜死亡以实现强效抗肿瘤治疗。

### 第二部分 AI 大师评价

本研究开发了一种创新的刺激响应性纳米平台，通过协同激活铜死亡和铁死亡两种新型细胞死亡机制来治疗三阴性乳腺癌。研究亮点在于巧妙设计了具有肿瘤微环境响应性和NIR-II光热增强功能的CuFeTe纳米片，不仅克服了肿瘤的抗氧化防御系统，还建立了两种死亡通路之间的协同放大效应。该策略的创新性在于首次将铜死亡和铁死亡有机结合，并利用光热效应加速氧化应激过程，最终诱导免疫原性细胞死亡和抗肿瘤免疫反应。虽然研究展现了良好的生物相容性和安全性，但其临床转化仍需进一步验证在复杂肿瘤微环境中的长期疗效和潜在毒性。这项工作为三阴性乳腺癌的治疗提供了新的思路，具有重要的临床转化价值。

---

## 52. Arid1a缺陷通过Ctnnb1突变和核苷酸切除修复缺陷驱动马兜铃酸诱导的肝脏肿瘤发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133886](https://pubmed.ncbi.nlm.nih.gov/41133886)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41133886
**DOI：** 10.1002/advs.202513981

### 第一部分 原文与翻译

**英文原标题：** Arid1a Deficiency Drives Aristolochic Acid-Induced Liver Tumorigenesis through Ctnnb1 Mutation and Defective Nucleotide Excision Repair.

**英文摘要原文：**
ARID1A, which encodes an important subunit of SWI/SNF complex, is frequently mutated in non-malignant tissues and tumors. However, how ARID1A loss enables environmental carcinogens to initiate tumorigenesis remains unknown. Here, liver-specific Arid1a-deficient (Arid1a) mice are exposed to aristolochic acid I (AAI), a potent herbal carcinogen. Notably, AAI dramatically accelerated hepatocarcinogenesis in Arid1a-deficient livers, accompanied by a specific 3' splice-site mutation in Ctnnb1 in most tumors and adjacent non-tumorous tissues. This mutation results in exon 3 skipping and subsequent β-catenin activation. Single-nucleus RNA-seq coupled with phylogenetic analyses reveals AAI-induced tumor microenvironment alteration and clonal expansion of β-catenin-activated cells. Conversely, inhibition of β-catenin signaling significantly suppresses AAI-induced tumors in the context of Arid1a loss. Mechanistically, Arid1a deficiency transcriptionally represses the expression of critical genes related to nucleotide excision repair, which removes AAI-derived DNA adducts, due to SWI/SNF complex dysfunction. Simultaneously, it upregulates Nqo1, a key enzyme enhancing AAI bioactivation and AAI-DNA adduct formation. This dual-hit mechanism, characterized by impaired DNA repair and heightened genotoxicity, explains synergistic carcinogenesis. The study unveils ARID1A as a guardian against environmental carcinogens and proposes β-catenin blockade for precision prevention in high-risk patients with ARID1A-mutant benign liver diseases.

**中文摘要译文：**
ARID1A编码SWI/SNF复合体的一个重要亚基，在非恶性组织和肿瘤中经常发生突变。然而，ARID1A缺失如何使环境致癌物启动肿瘤发生仍不清楚。本研究将肝脏特异性Arid1a缺陷小鼠暴露于马兜铃酸I（AAI），一种强效的草药致癌物。值得注意的是，AAI显著加速了Arid1a缺陷肝脏中的肝癌发生，并伴随大多数肿瘤和邻近非肿瘤组织中Ctnnb1的特异性3'剪接位点突变。该突变导致外显子3跳跃和随后的β-连环蛋白激活。单核RNA测序结合系统发育分析揭示了AAI诱导的肿瘤微环境改变和β-连环蛋白激活细胞的克隆扩增。相反，在Arid1a缺失的背景下，抑制β-连环蛋白信号通路显著抑制了AAI诱导的肿瘤。机制上，由于SWI/SNF复合体功能障碍，Arid1a缺陷转录抑制了与核苷酸切除修复相关的关键基因表达，而核苷酸切除修复负责清除AAI衍生的DNA加合物。同时，它上调了Nqo1，这是一种增强AAI生物活化和AAI-DNA加合物形成的关键酶。这种以DNA修复受损和遗传毒性增强为特征的双重打击机制解释了协同致癌作用。该研究揭示了ARID1A作为对抗环境致癌物的保护者，并提出了β-连环蛋白阻断用于ARID1A突变良性肝病高危患者的精准预防。

### 第二部分 AI 大师评价

本研究通过构建肝脏特异性Arid1a缺陷小鼠模型，深入揭示了ARID1A缺失与环境致癌物马兜铃酸协同促进肝癌发生的分子机制。研究创新性地发现Arid1a缺陷通过双重打击机制：一方面转录抑制核苷酸切除修复相关基因表达，另一方面上调AAI生物活化酶Nqo1，导致DNA修复能力下降和遗传毒性增强。关键发现包括特异性Ctnnb1剪接位点突变、β-连环蛋白激活以及肿瘤微环境重塑，为理解基因-环境相互作用在肿瘤发生中的作用提供了重要见解。该研究不仅阐明了ARID1A作为环境致癌物防护因子的新功能，还提出了针对ARID1A突变患者的β-连环蛋白靶向精准预防策略，具有重要的临床转化价值。

---

## 53. 靶向扩增Treg细胞诱导肾移植后免疫耐受

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41133815](https://pubmed.ncbi.nlm.nih.gov/41133815)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41133815
**DOI：** 10.1002/advs.202507943

### 第一部分 原文与翻译

**英文原标题：** Targeted Expansion of Treg Cells to Induce Immune Tolerance after Kidney Transplantation.

**英文摘要原文：**
Kidney transplantation remains the optimal treatment for end-stage renal disease, yet faces persistent challenges including organ shortages and risk of infection due to systemic immunosuppression. Cell therapy is expected to replace immunosuppressive agents. However, while Treg cell therapy can mitigate immune rejection, it fails to significantly prolong graft survival because peripherally induced Treg cells exhibit transdifferentiation potential in the circulatory system. Recent advances in nanocarrier systems offer promising approaches for achieving graft-specific immune tolerance. Through single-cell sequencing analysis, CD248 is identified as a pivotal stromal cell marker in renal allograft rejection, modulated by HIF-1α and IL-1β signaling pathways. Leveraging macrophage membrane coating technology, nanoparticles co-loaded is developed with IL-2 and TGF-β expressing plasmids. These nanoparticles incorporate a CD248-targeting antibody (IgG78) and plasmids containing a kidney-specific NPHS2 promoter, enabling dual-targeting capability for localized gene expression. In vitro validation demonstrated efficient differentiation of CD4⁺T cells into functional Treg populations. In rat renal transplantation models, nanoparticle treatment increased Treg cells in the graft and significantly prolonged allograft survival, improved renal function, and attenuated complement deposition. The findings establish a targeted nanoparticle platform that promotes graft-specific immune tolerance through localized Treg cell expansion, potentially reducing dependence on systemic immunosuppression.

**中文摘要译文：**
肾移植仍然是终末期肾病的最佳治疗方法，但仍面临持续挑战，包括器官短缺和因全身免疫抑制导致的感染风险。细胞疗法有望替代免疫抑制剂。然而，虽然Treg细胞疗法可以减轻免疫排斥反应，但由于外周诱导的Treg细胞在循环系统中表现出转分化潜能，因此无法显著延长移植物存活时间。纳米载体系统的最新进展为实现移植物特异性免疫耐受提供了有前景的方法。通过单细胞测序分析，CD248被确定为肾移植排斥反应中的关键基质细胞标志物，受HIF-1α和IL-1β信号通路调控。利用巨噬细胞膜包被技术，开发了共装载IL-2和TGF-β表达质粒的纳米颗粒。这些纳米颗粒整合了靶向CD248的抗体（IgG78）和含有肾脏特异性NPHS2启动子的质粒，实现了局部基因表达的双重靶向能力。体外验证表明，CD4⁺T细胞能够有效分化为功能性Treg群体。在大鼠肾移植模型中，纳米颗粒处理增加了移植物中的Treg细胞，显著延长了同种异体移植物存活时间，改善了肾功能，并减弱了补体沉积。这些发现建立了一个靶向纳米颗粒平台，通过局部Treg细胞扩增促进移植物特异性免疫耐受，可能减少对全身免疫抑制的依赖。

### 第二部分 AI 大师评价

本研究旨在开发一种靶向纳米颗粒平台，通过局部扩增调节性T细胞（Treg）来诱导肾移植后的免疫耐受。研究团队创新性地结合单细胞测序、巨噬细胞膜包被技术和双靶向策略，成功构建了能够特异性递送IL-2和TGF-β表达质粒的纳米颗粒。关键发现包括：CD248作为肾移植排斥的关键标志物，纳米颗粒处理显著延长了移植物存活时间并改善了肾功能。这项研究的创新性在于实现了移植物特异性的局部免疫调节，避免了传统Treg细胞疗法的转分化问题，具有重要的临床应用价值，可能为减少免疫抑制剂依赖提供新的治疗策略。然而，研究仍需进一步验证其在大型动物模型中的安全性和有效性。

---

## 54. 儿童胰腺实性假乳头状肿瘤的预后：一项系统评价与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41131672](https://pubmed.ncbi.nlm.nih.gov/41131672)
**期刊：** Annals of surgery
**PMID：** 41131672
**DOI：** 10.1097/SLA.0000000000006964

### 第一部分 原文与翻译

**英文原标题：** Outcomes in Paediatric Solid Pseudopapillary Neoplasms of the Pancreas: A Systematic Review and Meta-analysis.

**英文摘要原文：**
OBJECTIVE: To investigate outcomes and risk factors for recurrence and pancreatic insufficiency in paediatric Solid Pseudopapillary Neoplasm (SPN) of the pancreas.

BACKGROUND: SPN is a low-grade malignant pancreatic tumour and uncommon in children. Recommended treatment is complete surgical resection. Long-term problems include recurrence and pancreatic insufficiency. The low incidence in children complicates consolidation of high-quality data. Paediatric-specific guideline recommendations on follow-up are missing.

METHODS: Systematic review of Ovid/Medline/Embase/Web-of-Science databases from inception-2024, investigating outcomes after paediatric SPN resection. Meta-analysis, univariate and multivariate analysis were performed.

RESULTS: 778 articles were identified and 37 articles (701 patients) analysed. Median age was 14 years [IQR12;15], 584 (83.2%) patients were female. Median follow-up was 52.5 months [IQR 34;71]. Recurrence developed in 40 (5.7%) patients; at a median of41 months post-operatively [IQR 36;48]. Multivariate analysis identified positive resection margin (OR 48.1, P<0.001) and large tumour size (OR 1.44, P<0.001) associated with recurrence. Univariate analysis also identified neurovascular invasion and positive lymph node status as riskfactors. Endocrine dysfunction developed in 10/157 patients (median 14 mo [IQR 14;98] after surgery). Exocrine dysfunction developed in 9/157 patients: (median 15 mo [IQR 6;15]). Four (0.57%) patients died during reported follow-up, two with identified disease recurrence.

CONCLUSION: This meta-analysis of paediatric patients with SPN demonstrates a significantly increased risk of tumour recurrence in patients with larger tumours and positive resection margins, at a median of 3.4 years after surgery. This highlights the need for systematic long-term follow-up of children with SPN. International collaborative studies are warranted to improve paediatric-specific data.

**中文摘要译文：**
目的：探讨儿童胰腺实性假乳头状肿瘤（SPN）复发和胰腺功能不全的预后及危险因素。

背景：SPN是一种低度恶性的胰腺肿瘤，在儿童中较为罕见。推荐的治疗方法是完全手术切除。长期问题包括复发和胰腺功能不全。儿童发病率低使得高质量数据的整合变得复杂。缺乏针对儿童的随访指南建议。

方法：系统回顾了从建库至2024年的Ovid/Medline/Embase/Web of Science数据库，研究儿童SPN切除后的预后。进行了荟萃分析、单因素和多因素分析。

结果：共识别出778篇文章，分析了37篇文章（701例患者）。中位年龄为14岁[四分位距12;15]，584例（83.2%）患者为女性。中位随访时间为52.5个月[四分位距34;71]。40例（5.7%）患者发生复发，中位复发时间为术后41个月[四分位距36;48]。多因素分析确定阳性切缘（OR 48.1，P<0.001）和大肿瘤体积（OR 1.44，P<0.001）与复发相关。单因素分析还发现神经血管侵犯和阳性淋巴结状态是危险因素。10/157例患者发生内分泌功能障碍（中位术后14个月[四分位距14;98]）。9/157例患者发生外分泌功能障碍（中位术后15个月[四分位距6;15]）。在报告的随访期间有4例（0.57%）患者死亡，其中2例确认有疾病复发。

结论：这项针对儿童SPN患者的荟萃分析表明，肿瘤体积较大和阳性切缘的患者在术后中位3.4年时复发风险显著增加。这凸显了对SPN儿童进行系统性长期随访的必要性。需要开展国际合作研究以改善针对儿童的特定数据。

### 第二部分 AI 大师评价

本研究通过系统评价和荟萃分析，首次全面评估了儿童胰腺实性假乳头状肿瘤的长期预后和危险因素。研究创新性地整合了701例患者的临床数据，填补了儿童SPN领域高质量循证医学证据的空白。关键发现明确了阳性切缘和大肿瘤体积是复发的主要危险因素，复发率5.7%且多发生在术后3.4年左右，为临床随访策略提供了重要依据。该研究具有重要的临床指导价值，不仅揭示了术后胰腺功能不全的发生规律，还强调了制定儿童特异性随访指南的迫切性。主要局限性在于纳入研究的异质性和回顾性设计，未来需要更多前瞻性研究来验证这些发现。

---

## 55. 过氧化物氧化还原酶4作为调控肺泡巨噬细胞活化中PTEN/AKT轴的开关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41130939](https://pubmed.ncbi.nlm.nih.gov/41130939)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41130939
**DOI：** 10.1038/s41392-025-02454-x

### 第一部分 原文与翻译

**英文原标题：** Peroxiredoxin 4 as a switch regulating PTEN/AKT axis in alveolar macrophages activation.

**英文摘要原文：**
Phosphatase and tensin homolog (PTEN) is a critical inhibitor of the PI3K/AKT signaling pathway, yet its direct upstream regulators remain poorly defined. In this study, we investigated the role of peroxiredoxin 4 (PRDX4) in alveolar macrophages (AMs) activation and pulmonary fibrosis. Analyses of lung tissues from silicosis patients by transcriptomic and histological analyses revealed that PRDX4 is selectively upregulated in AMs and positively correlated with profibrotic and inflammatory gene expression. Consistent results were observed in silicosis model mice, where PRDX4 expression co-localized with the macrophage marker F4/80 and correlated with fibrotic indicators. Functional studies demonstrated that macrophage-specific silencing of PRDX4 using adeno-associated virus improved lung function and reduced inflammatory infiltration and fibrosis. PRDX4 upregulation aberrantly activated AMs and promoted epithelial-mesenchymal transition and fibroblast-myofibroblast transition. Mechanistically, PRDX4 enhanced AKT/NF-κB signaling with minimal effects on PI3K. Biochemical interaction assays further demonstrated that oligomeric PRDX4 disrupted PTEN homodimer formation, with mutational analyses identifying Cys124 and Cys245 as essential residues. Notably, Conoidin A alleviated crystalline silica-induced fibrosis in mice, with its therapeutic effect likely mediated by disrupting PRDX4 oligomerization. These findings identify PRDX4 as a novel upstream regulator of PTEN, establish a mechanistic PRDX4-PTEN axis in macrophage activation, and highlight PRDX4 as a promising therapeutic target for idiopathic pulmonary fibrosis and silicosis-associated fibrosis.

**中文摘要译文：**
磷酸酶和张力蛋白同源物（PTEN）是PI3K/AKT信号通路的关键抑制剂，但其直接上游调节因子仍不明确。本研究探讨了过氧化物氧化还原酶4（PRDX4）在肺泡巨噬细胞（AMs）活化和肺纤维化中的作用。通过对矽肺患者肺组织的转录组学和组织学分析发现，PRDX4在肺泡巨噬细胞中特异性上调，并与促纤维化和炎症基因表达呈正相关。在矽肺模型小鼠中观察到一致的结果，PRDX4表达与巨噬细胞标志物F4/80共定位，并与纤维化指标相关。功能研究表明，使用腺相关病毒进行巨噬细胞特异性PRDX4沉默可改善肺功能并减少炎症浸润和纤维化。PRDX4上调异常激活肺泡巨噬细胞，并促进上皮-间质转化和成纤维细胞-肌成纤维细胞转化。机制上，PRDX4增强AKT/NF-κB信号传导，对PI3K影响甚微。生化相互作用分析进一步证明，寡聚化PRDX4破坏PTEN同源二聚体形成，突变分析确定Cys124和Cys245为关键残基。值得注意的是，Conoidin A可减轻小鼠晶体二氧化硅诱导的纤维化，其治疗效果可能通过破坏PRDX4寡聚化介导。这些发现将PRDX4鉴定为PTEN的新型上游调节因子，建立了巨噬细胞活化中的PRDX4-PTEN轴机制，并突显PRDX4作为特发性肺纤维化和矽肺相关纤维化的有前景治疗靶点。

### 第二部分 AI 大师评价

本研究通过整合临床样本分析、动物模型验证和分子机制探索，系统阐明了PRDX4在肺纤维化发病机制中的关键作用。研究创新性地发现PRDX4通过破坏PTEN同源二聚体形成来调控PTEN/AKT轴，这一机制为理解PTEN上游调控提供了新视角。研究不仅揭示了PRDX4作为肺泡巨噬细胞活化的分子开关，还验证了靶向PRDX4寡聚化的治疗策略，为特发性肺纤维化和矽肺相关纤维化的治疗提供了新的潜在靶点。尽管研究在机制层面取得了重要突破，但临床转化仍需进一步验证其安全性和有效性。

---

速递结束，祝您工作愉快！